DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Fluorescence-based assay are 1074

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0368	Amlodipine Besylate	Cardiovascular agents	Hypertension and chronic stable angina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0369	Azelastine	Respiratory System	Rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0370	Benztropine Mesylate	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0371	Cephapirin Sodium	Antibiotics	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0372	Chlorhexidine Diacetate	Alimentary Tract and Metabolism	Disinfectant, oropharyngeal decontamination	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0373	Ciclesonide	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0374	Cilastatin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0375	Clemastine Fumarate	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0376	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0377	Clomipramine Hydrochloride	Nervous System	Obsessive-compulsive disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0378	Danazol	Genito Urinary System and Sex Hormones	Endometriosis and fibrocystic breast disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0379	Deslanoside	Cardiovascular agents	Congestive cardiac insufficiency, arrhythmias and heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0380	Dicyclomine Hydrochloride	Alimentary Tract and Metabolism	Bowel/irritable bowel syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0381	Digitoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0382	Digoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0383	Doxylamine Succinate	Respiratory System	Cough, vomiting and nausea	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0384	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0385	Fluphenazine Hydrochloride	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0386	Fluvastatin	Cardiovascular agents	Cardiovascular disease (Coronary heart disease (CHD))	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0387	Guanethidine Monosulfate	Cardiovascular agents	Hypertension	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0388	Hexachlorophene	Dermatologicals	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0389	Hycanthone	Antischistosomal	Parasitic infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0390	Hydroxyprogesterone Caproate	Genito Urinary System and Sex Hormones	Spontaneous preterm births	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0391	Loperamide	Alimentary Tract and Metabolism	Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0392	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0393	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Vet approved	26041706
DrugRepV_0394	Methdilazine Hydrochloride	Respiratory System	Hypersensitivity reactions | Skin disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0395	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0396	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0397	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0398	Nonoxynol-9	Gynaecological-agents	Contraception	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0399	Paroxetine Hydrochloride Hemihydrate	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0400	Pentamidine	Antiparasitic products, Insectisides and Repellents	Pneumonia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0401	Perhexiline Maleate	Cardiovascular agents	Angina pectoris	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0402	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0403	Podofilox	Dermatologicals	External genital warts	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0404	Prochlorperazine Edisylate	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Vet approved	26041706
DrugRepV_0405	Pyrvinium Pamoate	Antiparasitic products, Insectisides and Repellents	Pinworm infestations	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0406	Quinacrine Dihydrochloride	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0407	Quinestrol	Gynaecological-agents	Hormone replacement therapy | Treating symptoms of menopause such as hot flashes | Breast cancer | Prostate cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0408	Raloxifene Hydrochloride	Genito Urinary System and Sex Hormones	Osteoporosis | Corticosteroid-induced bone loss	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0409	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0410	Sorafenib Tosylate	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0411	Sunitinib Malate	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0412	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0413	Tamoxifen Citrate	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0414	Thioridazine Hydrochloride	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0415	Tioconazole	Dermatologicals; Genito Urinary System and Sex Hormones	Vulvovaginal candidiasis (moniliasis)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0416	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0417	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0418	Trifluoperazine Hydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0419	Triflupromazine Hydrochloride	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0420	Vinorelbine Tartrate Hydrate	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	NA	26041706
DrugRepV_0421	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0422	Astemizole	Respiratory System	Allergies	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0423	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0424	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0425	Benztropine	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0426	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0427	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0428	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0429	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0430	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0431	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0432	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0433	Fluphenazine	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0434	Hycanthone	Antischistosomal	Parasitic infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0435	Lomerizine	Neurologic-agent	Migraine disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0436	Maprotiline	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0437	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0438	Pimozide	Nervous System	Tourette Disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0439	Piperacetazine	Antipsychotic	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	NA	26041706
DrugRepV_0440	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0441	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0442	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0443	Simvastatin	Cardiovascular agents	Hypercholesterolemia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0444	Strophanthin	Cardiovascular agents	Atrial fibrillation | Flutter | Heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0445	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0446	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0447	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0448	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0449	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0450	Astemizole	Respiratory System	Allergies	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0451	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0452	Benztropine	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0453	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0454	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0455	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0456	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0457	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0458	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0459	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0460	Fluphenazine	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0461	Hycanthone	Antischistosomal	Parasitic infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0462	Lomerizine	Neurologic-agent	Migraine disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0463	Maprotiline	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0464	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0465	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0466	Pimozide	Nervous System	Tourette Disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0467	Piperacetazine	Antipsychotic	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	NA	26041706
DrugRepV_0468	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0469	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0470	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0471	Strophanthin	Cardiovascular agents	Atrial fibrillation | Flutter | Heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0472	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0473	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0474	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0475	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0476	Vinorelbine	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0509	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	EBOV/Kik	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0510	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	SUDV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0511	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	MARV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0512	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	RAVV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0513	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV/Kik	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0514	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV/May	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0515	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	SUDV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0516	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	MARV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0517	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	RAVV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0518	Vinblastine	Antineoplastic and Immunomodulating Agents	Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0519	Vinorelbine	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0520	Vincristine	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0521	Colchicine	Musculo-Skeletal System	Gout	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0522	Nocodazole	Anticancer	NA	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26038505
DrugRepV_0523	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0524	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0525	Digoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0526	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0527	Raloxifene/Evista	Genito Urinary System and Sex Hormones	Osteoporosis | Corticosteroid-induced bone loss	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0528	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0529	Thiothixene	Nervous System	Schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0530	Dronedarone	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0531	Maprotiline	Nervous System	Bipolar depression	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0532	Daunorubicin	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0533	Benztropine	Nervous System	Parkinson disease	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0534	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0535	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Vet approved	26038505
DrugRepV_0536	Trifluoperazine	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0537	Clarithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0538	Albendazole	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0539	Clomipramine	Nervous System	Depressive disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0540	Propafenone	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0541	Carfilzomib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0542	Deslanoside	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0543	Maduramicin	Antiprotozoal	Coccidiosis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Vet approved	26038505
DrugRepV_0544	Cepharanthine	Antiinflammatory and antineoplastic	Inflammatory disorders/Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0545	Clomiphene	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0546	Oxibendazole	Antiparasitic	Helminth intestinal infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Investigational, Vet approved	26038505
DrugRepV_0547	Daunorubicin	Antineoplastic and Immunomodulating Agents	Microbial infections and cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0548	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0549	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0550	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0551	Tilorone	NA	Acquired immunodeficiency syndrome	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0552	Bazedoxifene	Genito Urinary System and Sex Hormones	Postmenopausal osteoporosis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0553	Topotecan	Antineoplastic and Immunomodulating Agents	Ovarian cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0554	Bosutinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0555	Thioproperazine	Nervous System	Psychosis | Acute and Chronic schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0556	Spiramycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0557	Mibefradil	Cardiovascular agents	Angina | High blood pressure	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Investigational, Withdrawn	26038505
DrugRepV_0558	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0559	Nitrovin	NA	NA	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0560	Bifemelane	Nervous System	Depressive disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26038505
DrugRepV_0561	Bitolterol	Respiratory System	Bronchodilator	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Withdrawn	26038505
DrugRepV_0562	Proglumetacin	Musculo-Skeletal System	Inflammatory disorders	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26038505
DrugRepV_0563	Aprindine	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0564	Cyclomethycaine	NA	Anesthesia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Withdrawn	26038505
DrugRepV_0565	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Vet approved	26038505
DrugRepV_0566	Alverine Citrate	Alimentary Tract and Metabolism	Muscle spasms	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0567	Azaclorzine	NA	Anginal	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0568	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0569	Piperacetazine	Antipsychotic	Schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0570	Gefitinib	Antineoplastic and Immunomodulating Agents	Non-small cell lung cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0571	Imipramine	Nervous System	Depression	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0572	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0573	Nilotinib	Antineoplastic and Immunomodulating Agents	Leukemias | Chronic myeloid leukemia (CML)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0581	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23785035
DrugRepV_0582	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23785035
DrugRepV_0583	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0584	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0692	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0693	Biperiden	Nervous System	Parkinson disease	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0694	Carprofen	Anti-inflammatory	Joint pain	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Withdrawn	23577127
DrugRepV_0695	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0696	Dibucaine	Nervous System	Anesthesia	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0697	Diphenoxylate	Alimentary Tract and Metabolism	Diarrhea	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0698	Diphenylpyraline	Respiratory System	Allergies	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0699	Dipivefrin	Sensory Organ	Glaucoma	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0700	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0701	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0702	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0703	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Vet approved	23577127
DrugRepV_0704	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0705	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Investigational	23577127
DrugRepV_0706	Oxyphencyclimine	Alimentary Tract and Metabolism	Peptic ulcers	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0707	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Investigational	23577127
DrugRepV_0708	Trihexyphenidyl	Nervous System	Parkinson Disease	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0721	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23577127
DrugRepV_0722	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23577127
DrugRepV_0723	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23577127
DrugRepV_0724	Aminoquinoline-13	NA	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	NA	23577127
DrugRepV_0732	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23129053
DrugRepV_0733	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		Fluorescence-based assay	Decrease (3 Fold)	Approved, Investigational	23129053
DrugRepV_0734	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/New/ Caledonia/20/99		Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23129053
DrugRepV_0735	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/California/07/09		Fluorescence-based assay	Decrease (25 %)	Approved, Investigational	23129053
DrugRepV_0736	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/Philippines/2/82/X-79		Fluorescence-based assay	Decrease (15 %)	Approved, Investigational	23129053
DrugRepV_0760	Clofazimine	Antiinfectives For Systemic Use	Lepromatous leprosy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.665 %)	Approved	27476412
DrugRepV_0761	Digoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (100 %)	Approved	27476412
DrugRepV_0762	Gemcitabine Hydrochloride	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.955 %)	Approved	27476412
DrugRepV_0763	Idarubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Acute myeloid leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (100 %)	Approved	27476412
DrugRepV_0764	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.52 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0765	Mefloquine Hydrochloride	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.815 %)	Approved, Investigational	27476412
DrugRepV_0766	Mercaptopurine Hydrate	Antineoplastic and Immunomodulating Agents	Acute lymphatic leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.425 %)	Approved	27476412
DrugRepV_0767	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.845 %)	Approved	27476412
DrugRepV_0768	Tacrolimus	Antineoplastic and Immunomodulating Agents	Allogenic organ transplant (kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (100 %)	Approved	27476412
DrugRepV_0769	Epirubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.23 %)	Approved	27476412
DrugRepV_0770	Fingolimod	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.18 %)	Approved	27476412
DrugRepV_0771	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.825 %)	Approved, Investigational	27476412
DrugRepV_0772	Dactinomycin	NA	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.435 %)	Approved	27476412
DrugRepV_0773	Methotrexate	NA	Gestational choriocarcinoma | Chorioadenoma destruens | Hydatidiform mole | Meningeal leukemia | Breast cancer | Epidermoid cancers of the head and neck | Lung cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (97.715 %)	Approved	27476412
DrugRepV_0774	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (98.03 %)	Approved	27476412
DrugRepV_0775	Chlorhexidine Dihydrochloride	Alimentary Tract and Metabolism	Disinfectant, oropharyngeal decontamination	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (97.965 %)	Approved	27476412
DrugRepV_0776	Methoxsalen	Dermatologicals	Psoriasis | Vitiligo	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (94.295 %)	Approved	27476412
DrugRepV_0777	Azathioprine	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis.	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (96.385 %)	Approved	27476412
DrugRepV_0778	Thioguanine	Antineoplastic and Immunomodulating Agents	Acute leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (95.295 %)	Approved	27476412
DrugRepV_0779	Auranofin	Musculo-Skeletal System	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (93.84 %)	Approved	27476412
DrugRepV_0780	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (89 %)	Approved	27476412
DrugRepV_0781	Pyrimethamine	Antiparasitic products, Insectisides and Repellents	Toxoplasmosis | Acute malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (83.105 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0782	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (89.915 %)	Approved	27476412
DrugRepV_0783	Palonosetron Hydrochloride	Alimentary Tract and Metabolism	Nausea and vomiting associated with cancer chemotherapy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (87.615 %)	Approved, Investigational	27476412
DrugRepV_0784	Deferasirox	Various	Tansfusional hemosiderosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (87.47 %)	Approved	27476412
DrugRepV_0785	Micafungin	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (86.88 %)	Approved, Investigational	27476412
DrugRepV_0786	Trifluoperazine Hydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (70.37 %)	Approved	27476412
DrugRepV_0787	Nebivolol Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (72.455 %)	Approved, Investigational	27476412
DrugRepV_0788	Sorafenib Tosylate	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (82.225 %)	Approved, Investigational	27476412
DrugRepV_0789	Ethinyl estradiol	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (77.81 %)	Approved	27476412
DrugRepV_0790	Pimecrolimus	Dermatologicals	Atopic dermatitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (71.825 %)	Approved, Investigational	27476412
DrugRepV_0791	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (82.105 %)	Approved	27476412
DrugRepV_0792	Sunitinib Malate	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (73.145 %)	Approved, Investigational	27476412
DrugRepV_0793	Pimozide	Nervous System	Tourette Disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (72.91 %)	Approved	27476412
DrugRepV_0794	Thioridazine Hydrochloride	Nervous System	Schizophrenia | Anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (69.315 %)	Approved, Withdrawn	27476412
DrugRepV_0795	Paclitaxel	Antineoplastic and Immunomodulating Agents	Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (78.59 %)	Approved	27476412
DrugRepV_0796	Docetaxel	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (79.61 %)	Approved	27476412
DrugRepV_0797	Prazosin Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (79.755 %)	Approved	27476412
DrugRepV_0798	Tolvaptan	Cardiovascular agents	Hyponatremia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (71.575 %)	Approved	27476412
DrugRepV_0799	Hexachlorophene	Dermatologicals	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (73.95 %)	Approved, Withdrawn	27476412
DrugRepV_0800	Eplerenone	Cardiovascular agents	Left ventricular systolic dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.435 %)	Approved	27476412
DrugRepV_0801	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (71.81 %)	Approved, Vet approved	27476412
DrugRepV_0802	Cilostazol	Blood and Blood Forming Organs	Intermittent claudication	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (67.75 %)	Approved	27476412
DrugRepV_0803	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.34 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0804	Dutasteride	Genito Urinary System and Sex Hormones	Prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.475 %)	Approved	27476412
DrugRepV_0805	Pazopanib Hydrochloride	Antineoplastic and Immunomodulating Agents	Advanced renal cell cancer | Advanced soft tissue sarcoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (70.75 %)	Approved	27476412
DrugRepV_0806	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.91 %)	Approved, Investigational	27476412
DrugRepV_0807	Vinorelbine	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (67.24 %)	Approved	27476412
DrugRepV_0808	Vorinostat	Antineoplastic and Immunomodulating Agents	T-cell lymphoma (CTCL, a type of cancer)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (70.85 %)	Approved	27476412
DrugRepV_0809	Deferoxamine Mesylate	Various	Iron or aluminum toxicity	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (67.29 %)	Approved	27476412
DrugRepV_0810	Bexarotene	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (69.51 %)	Approved	27476412
DrugRepV_0811	Podofilox	Dermatologicals	External genital warts	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (63.735 %)	Approved	27476412
DrugRepV_0812	Colchicine	Musculo-Skeletal System	Gout	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.075 %)	Approved	27476412
DrugRepV_0813	Nilotinib	Antineoplastic and Immunomodulating Agents	Leukemias | Chronic myeloid leukemia (CML)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (63.05 %)	Approved, Investigational	27476412
DrugRepV_0814	Albendazole	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (68.09 %)	Approved	27476412
DrugRepV_0815	Ciclesonide	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.46 %)	Approved	27476412
DrugRepV_0816	Meclizine Dihydrochloride	Respiratory System	Nausea | Vomiting | Motion sickness | Vertigo	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.685 %)	Approved	27476412
DrugRepV_0817	Tazarotene	Dermatologicals	Psoriasis, acne and sun damaged skin	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.1 %)	Approved	27476412
DrugRepV_0818	Moexipril Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.935 %)	Approved	27476412
DrugRepV_0819	Vinblastine Sulfate	Antineoplastic and Immunomodulating Agents	Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.755 %)	Approved	27476412
DrugRepV_0820	Trospium Chloride	Genito Urinary System and Sex Hormones	Overactive bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.11 %)	Approved	27476412
DrugRepV_0821	Econazole Nitrate	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (69.6 %)	Approved	27476412
DrugRepV_0822	Prednisone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.325 %)	Approved, Vet approved	27476412
DrugRepV_0823	Calcipotriene	Dermatologicals	Psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.795 %)	Approved	27476412
DrugRepV_0824	Rabeprazole Sodium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) | Peptic ulcer disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.765 %)	Approved, Investigational	27476412
DrugRepV_0825	Pitavastatin Calcium	Cardiovascular agents	Dyslipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (62.655 %)	Approved	27476412
DrugRepV_0826	Risperidone	Nervous System	Schizophrenia | Mood disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (63.025 %)	Approved, Investigational	27476412
DrugRepV_0827	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.085 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0828	Irbesartan	Cardiovascular agents	Hypertension | Diabetic nephropathy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.84 %)	Approved, Investigational	27476412
DrugRepV_0829	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.145 %)	Approved	27476412
DrugRepV_0830	Triamterene	Cardiovascular agents	Edema associated with congestive heart failure | Cirrhosis of the liver | Nephrotic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.03 %)	Approved	27476412
DrugRepV_0831	Mitomycin C	Antineoplastic and Immunomodulating Agents	Malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (64.305 %)	Approved	27476412
DrugRepV_0832	Ciclopirox	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.575 %)	Approved	27476412
DrugRepV_0833	Doxorubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.365 %)	Approved	27476412
DrugRepV_0834	Cisatracurium Besylate	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.815 %)	Approved	27476412
DrugRepV_0835	Tolcapone	Nervous System	Parkinson's Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.86 %)	Approved, Withdrawn	27476412
DrugRepV_0836	Primaquine Phosphate	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.24 %)	Approved	27476412
DrugRepV_0837	Exemestane	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.61 %)	Approved	27476412
DrugRepV_0838	Pentamidine Isethionate	Antiparasitic products, Insectisides and Repellents	Pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.63 %)	Approved, Investigational	27476412
DrugRepV_0839	Isoniazid	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.29 %)	Approved, Investigational	27476412
DrugRepV_0840	Zaleplon	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.615 %)	Approved	27476412
DrugRepV_0841	Pravastatin Sodium	Cardiovascular agents	Hypercholesterolemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.5 %)	Approved	27476412
DrugRepV_0842	Clofarabine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (62.94 %)	Approved	27476412
DrugRepV_0843	Penicillin G Potassium	Antiinfectives For Systemic Use	Septicemia | Meningitis | Pericarditis | Endocarditis | Pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.15 %)	Approved	27476412
DrugRepV_0844	Etonogestrel	Genito Urinary System and Sex Hormones	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.965 %)	Approved	27476412
DrugRepV_0845	Alitretinoin	Dermatologicals	Cutaneous lesions in patients with AIDS-related Kaposi sarcoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.94 %)	Approved	27476412
DrugRepV_0846	Cefuroxime Axetil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.5 %)	Approved	27476412
DrugRepV_0847	Mesna	Respiratory System; Various	Hemorrhagic cystitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.73 %)	Approved, Investigational	27476412
DrugRepV_0848	Levonorgestrel	Genito Urinary System and Sex Hormones	Menopausal and postmenopausal disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.52 %)	Approved, Investigational	27476412
DrugRepV_0849	Nystatin	Alimentary Tract And Metabolism; Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.71 %)	Approved	27476412
DrugRepV_0850	Olopatadine	Sensory Organ	Allergic conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.77 %)	Approved	27476412
DrugRepV_0851	Acetylcysteine	Respiratory System; Sensory Organ; Various	Acetaminophen poisoning	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.525 %)	Approved	27476412
DrugRepV_0852	Linezolid	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.395 %)	Approved, Investigational	27476412
DrugRepV_0853	Vincristine Sulfate	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (62.91 %)	Approved, Investigational	27476412
DrugRepV_0854	Metaraminol Bitartrate	Cardiovascular agents	Hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.365 %)	Approved, Investigational	27476412
DrugRepV_0855	Raloxifene Hydrochloride	Genito Urinary System and Sex Hormones	Osteoporosis | Corticosteroid-induced bone loss	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.245 %)	Approved, Investigational	27476412
DrugRepV_0856	Lincomycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.795 %)	Approved, Vet approved	27476412
DrugRepV_0857	Atorvastatin Calcium	Cardiovascular agents	Coronary heart disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.57 %)	Approved	27476412
DrugRepV_0858	Calcitriol	Alimentary Tract and Metabolism	Vitamin D resistant rickets	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.57 %)	Approved	27476412
DrugRepV_0859	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.53 %)	Approved	27476412
DrugRepV_0860	Megestrol Acetate	Genito Urinary System and Sex Hormones	Anorexia | Cachexia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.545 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0861	Pralidoxime Chloride	Various	Poisoning	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.51 %)	Approved, Vet approved	27476412
DrugRepV_0862	Chenodiol	Alimentary Tract and Metabolism	Radiolucent stones	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.095 %)	Approved	27476412
DrugRepV_0863	Tretinoin	Dermatologicals; Antineoplastic and Immunomodulating Agents	Acne | Photodamaged skin | Keratinization disorders such as ichthyosis and keratosis follicularis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.47 %)	Approved	27476412
DrugRepV_0864	Vancomycin Hydrochloride	Alimentary Tract And Metabolism; Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.91 %)	Approved	27476412
DrugRepV_0865	Prasugrel	Blood and Blood Forming Organs	Acute coronary syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.09 %)	Approved	27476412
DrugRepV_0866	Acrivastine	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.315 %)	Approved	27476412
DrugRepV_0867	Mequinol	Dermatologicals	Solar lentigines | Hyperpigmented lesions	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.96 %)	Approved	27476412
DrugRepV_0868	Bromocriptine Mesylate	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.805 %)	Approved	27476412
DrugRepV_0869	Donepezil Hydrochloride	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.885 %)	Approved	27476412
DrugRepV_0870	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.1 %)	Approved	27476412
DrugRepV_0871	Methazolamide	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.695 %)	Approved	27476412
DrugRepV_0872	Probenecid	Musculo-Skeletal System	Gout	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.465 %)	Approved, Investigational	27476412
DrugRepV_0873	Carbachol Chloride	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.395 %)	Approved	27476412
DrugRepV_0874	Nortriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.8 %)	Approved	27476412
DrugRepV_0875	Colistimethate Sodium	Alimentary Tract And Metabolism; Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.695 %)	Approved	27476412
DrugRepV_0876	Norfloxacin	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.51 %)	Approved	27476412
DrugRepV_0877	Simvastatin	Cardiovascular agents	Hypercholesterolemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.405 %)	Approved	27476412
DrugRepV_0878	Amphotericin B	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.04 %)	Approved	27476412
DrugRepV_0879	Ziprasidone Hydrochloride	Nervous System	Schizophrenia and psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.475 %)	Approved	27476412
DrugRepV_0880	Fluphenazine Hydrochloride	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.715 %)	Approved	27476412
DrugRepV_0881	Metoclopramide Hydrochloride	Alimentary Tract and Metabolism	Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.405 %)	Approved, Investigational	27476412
DrugRepV_0882	Mepenzolate Bromide	Alimentary Tract and Metabolism	Peptic ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.065 %)	Approved	27476412
DrugRepV_0883	Eptifibatide	Blood and Blood Forming Organs	Myocardial infarction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.02 %)	Approved	27476412
DrugRepV_0884	Oxtriphylline	Respiratory System	Asthma | Bronchospasm | Chronic Obstructive Pulmonary Disease (COPD)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.265 %)	Approved	27476412
DrugRepV_0885	Procarbazine Hydrochloride	Antineoplastic and Immunomodulating Agents	Hodgkin's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.4 %)	Approved	27476412
DrugRepV_0886	Ketoconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.415 %)	Approved, Investigational	27476412
DrugRepV_0887	Trazodone Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.415 %)	Approved, Investigational	27476412
DrugRepV_0888	Ceftibuten	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.895 %)	Approved	27476412
DrugRepV_0889	Fluvastatin Sodium	Cardiovascular agents	Cardiovascular disease (Coronary heart disease (CHD))	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.69 %)	Approved	27476412
DrugRepV_0890	Acetazolamide	Sensory Organ	Edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.035 %)	Approved	27476412
DrugRepV_0891	Chlorzoxazone	Musculo-Skeletal System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.755 %)	Approved	27476412
DrugRepV_0892	Naltrexone Hydrochloride	Nervous System	Alcohol dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.515 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0893	Perindopril Erbumine	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.56 %)	Approved	27476412
DrugRepV_0894	Prednisolone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.415 %)	Approved, Vet approved	27476412
DrugRepV_0895	Nefazodone Hydrochloride	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.595 %)	Approved, Withdrawn	27476412
DrugRepV_0896	Prilocaine Hydrochloride	NA	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.97 %)	Approved	27476412
DrugRepV_0897	Quinidine Hydrochloride Hydrate	Cardiovascular agents	Ventricular pre-excitation | Cardiac dysrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.385 %)	Approved, Investigational	27476412
DrugRepV_0898	Acarbose	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.59 %)	Approved	27476412
DrugRepV_0899	Progesterone	Genito Urinary System and Sex Hormones	Infertility	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.635 %)	Approved, Vet approved	27476412
DrugRepV_0900	Tetrabenazine	Nervous System	Huntington disease | Hemiballismus | Senile chorea | Tourette syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.175 %)	Approved	27476412
DrugRepV_0901	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.92 %)	Approved	27476412
DrugRepV_0902	Danazol	Genito Urinary System and Sex Hormones	Endometriosis and fibrocystic breast disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.385 %)	Approved	27476412
DrugRepV_0903	Estropipate	Genito Urinary System and Sex Hormones	Vaginal atrophy associated with the menopause	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.39 %)	Approved	27476412
DrugRepV_0904	Clopidogrel Hydrogen Sulfate	Blood and Blood Forming Organs	Myocardial infarction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.555 %)	Approved	27476412
DrugRepV_0905	Lovastatin	Cardiovascular agents	Atherosclerotic vascular disease | Hypercholesterolemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.375 %)	Approved, Investigational	27476412
DrugRepV_0906	Sertaconazole	Dermatologicals; Genito Urinary System and Sex Hormones	Fungal infections (Tinea pedis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.215 %)	Approved, Investigational	27476412
DrugRepV_0907	Ofloxacin	Antiinfectives For Systemic Use	Respiratory tract infections | Kidney infection | Skin infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.695 %)	Approved	27476412
DrugRepV_0908	Acetohydroxamic Acid	Genito Urinary System and Sex Hormones	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.495 %)	Approved	27476412
DrugRepV_0909	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.495 %)	Approved	27476412
DrugRepV_0910	Tacrine Hydrochloride	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.39 %)	Approved	27476412
DrugRepV_0911	L-Ascorbic Acid	Alimentary Tract and Metabolism	Vitamin C deficiency | Scurvy | Delayed wound and bone healing | Urine acidification	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.58 %)	Approved, Nutraceutical	27476412
DrugRepV_0912	Nepafenac	Sensory Organ	Inflammation associated with cataract surgery	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.565 %)	Approved	27476412
DrugRepV_0913	Ambrisentan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.165 %)	Approved	27476412
DrugRepV_0914	Imiquimod	Dermatologicals	Genital and perianal warts/condyloma acuminata	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.785 %)	Approved, Investigational	27476412
DrugRepV_0915	Loperamide Hydrochloride	Alimentary Tract and Metabolism	Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.78 %)	Approved	27476412
DrugRepV_0916	Methyl Aminolevulinate Hydrochloride	Antineoplastic and Immunomodulating Agents	Non-hyperkeratotic actinic keratoses	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.34 %)	Approved	27476412
DrugRepV_0917	Etodolac	Musculo-Skeletal System	Osteoarthritis and rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.89 %)	Approved	27476412
DrugRepV_0918	Cephalexin Monohydrate	Antibiotics	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.225 %)	Approved	27476412
DrugRepV_0919	Metaproterenol Hemisulfate	Respiratory System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.225 %)	Approved	27476412
DrugRepV_0920	Acitretin	Dermatologicals	Psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.15 %)	Approved	27476412
DrugRepV_0921	Oxybutynin Chloride	Genito Urinary System and Sex Hormones	Overactive bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.105 %)	Approved, Investigational	27476412
DrugRepV_0922	Oxcarbazepine	Nervous System	Partial seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.92 %)	Approved	27476412
DrugRepV_0923	Amikacin Disulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.975 %)	Approved	27476412
DrugRepV_0924	Ciprofloxacin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.87 %)	Approved	27476412
DrugRepV_0925	Duloxetine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.7 %)	Approved	27476412
DrugRepV_0926	Spectinomycin Hydrochloride Pentahydrate	Antiinfectives For Systemic Use	Bacterial infections (Gonorrheal urethritis and proctitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.825 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0927	Famotidine	Alimentary Tract and Metabolism	Peptic ulcer | Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.495 %)	Approved	27476412
DrugRepV_0928	Triamcinolone Acetonide	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.745 %)	Approved, Vet approved	27476412
DrugRepV_0929	Methacholine Chloride	Nervous System	Bronchial hyperreactivity	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.51 %)	Approved, Investigational	27476412
DrugRepV_0930	Apomorphine Hydrochloride Hemihydrate	Nervous System	Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.305 %)	Approved	27476412
DrugRepV_0931	Nilutamide	Antineoplastic and Immunomodulating Agents	Metastatic prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.885 %)	Approved, Investigational	27476412
DrugRepV_0932	Almotriptan	Nervous System	Acute migraine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.88 %)	Approved	27476412
DrugRepV_0933	Felbamate	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.745 %)	Approved	27476412
DrugRepV_0934	Pantoprazole	Alimentary Tract and Metabolism	Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.82 %)	Approved	27476412
DrugRepV_0935	Lamotrigine	Nervous System	Epilepsy and bipolar disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.015 %)	Approved, Investigational	27476412
DrugRepV_0936	Chlorthalidone	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.405 %)	Approved	27476412
DrugRepV_0937	Penicillin V Potassium	Antiinfectives For Systemic Use	Mild to moderately severe infections due to penicillin G­-sensitive microorganisms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.165 %)	Approved	27476412
DrugRepV_0938	Ceftriaxone Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.04 %)	Approved	27476412
DrugRepV_0939	Scopolamine Hydrobromide	Alimentary Tract And Metabolism; Nervous System; Sensory Organ	Irritable bowel syndrome | Excessive salivation | Motion sickness	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.095 %)	Approved, Investigational	27476412
DrugRepV_0940	Acetaminophen	Nervous System	Fever, minor aches and pains	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.27 %)	Approved	27476412
DrugRepV_0941	Alosetron Hydrochloride	Alimentary Tract and Metabolism	Diarrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.005 %)	Approved	27476412
DrugRepV_0942	Meclofenamate Sodium	Musculo-Skeletal System	Pain | Primary dysmenorrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.11 %)	Approved, Vet approved	27476412
DrugRepV_0943	Varenicline Tartrate	Nervous System	Nicotine dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.14 %)	Approved	27476412
DrugRepV_0944	Acetohexamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.13 %)	Approved, Withdrawn	27476412
DrugRepV_0945	Crotamiton	Antipruritic agent	Scabies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.21 %)	Approved	27476412
DrugRepV_0946	Sulindac	Musculo-Skeletal System	Osteoarthritis | Rheumatoid arthritis | Ankylosing spondylitis | Acute painful shoulder | Acute gouty arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.295 %)	Approved, Investigational	27476412
DrugRepV_0947	Rosiglitazone	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.78 %)	Approved	27476412
DrugRepV_0948	Acebutolol Hydrochloride	Cardiovascular agents	Hypertension and ventricular premature beats	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.335 %)	Approved	27476412
DrugRepV_0949	Procainamide Hydrochloride	Cardiovascular agents	Ventricular arrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.96 %)	Approved	27476412
DrugRepV_0950	Atropine Sulfate Monohydrate	Sensory Organ	Cholinesterase	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.08 %)	Approved	27476412
DrugRepV_0951	Bupropion	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.045 %)	Approved	27476412
DrugRepV_0952	Febuxostat	Musculo-Skeletal System	Hyperuricemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.325 %)	Approved	27476412
DrugRepV_0953	Valsartan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.425 %)	Approved	27476412
DrugRepV_0954	Nitisinone	Alimentary Tract and Metabolism	Hereditary tyrosinemia type 1	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.205 %)	Approved	27476412
DrugRepV_0955	Guanfacine Hydrochloride	NA	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.975 %)	Approved, Investigational	27476412
DrugRepV_0956	Valproate Sodium	Nervous System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.71 %)	Approved	27476412
DrugRepV_0957	Primidone	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.36 %)	Approved, Vet approved	27476412
DrugRepV_0958	Halcinonide	Dermatologicals	Dermatoses	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.67 %)	Approved, Investigational, Withdrawn	27476412
DrugRepV_0959	Eszopiclone	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.415 %)	Approved	27476412
DrugRepV_0960	Haloperidol	Nervous System	Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.42 %)	Approved	27476412
DrugRepV_0961	Pioglitazone Hydrochloride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.685 %)	Approved, Investigational	27476412
DrugRepV_0962	Epinephrine	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory	Anaphylaxis and sepsis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.39 %)	Approved	27476412
DrugRepV_0963	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.235 %)	Approved	27476412
DrugRepV_0964	Pilocarpine Hydrochloride	Sensory Organ	Xerostomia | Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.575 %)	Approved, Investigational	27476412
DrugRepV_0965	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.69 %)	Approved	27476412
DrugRepV_0966	Chlorothiazide	Cardiovascular agents	Edema associated with congestive heart failure, hepatic cirrhosis and hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.72 %)	Approved	27476412
DrugRepV_0967	Chlorpropamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.46 %)	Approved	27476412
DrugRepV_0968	Ethionamide	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.99 %)	Approved	27476412
DrugRepV_0969	Praziquantel	Antiparasitic products, Insectisides and Repellents	Schistosomiasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.16 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0970	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.93 %)	Approved	27476412
DrugRepV_0971	Iloperidone	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.515 %)	Approved	27476412
DrugRepV_0972	Etomidate	Nervous System	General anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.365 %)	Approved	27476412
DrugRepV_0973	Zonisamide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.085 %)	Approved	27476412
DrugRepV_0974	Oxacillin Sodium salt Monohydrate	Antiinfectives For Systemic Use	Staphylococci infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.525 %)	Approved, Investigational	27476412
DrugRepV_0975	Fexofenadine Hydrochloride	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.055 %)	Approved	27476412
DrugRepV_0976	Phenytoin	Nervous System	Seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.54 %)	Approved, Vet approved	27476412
DrugRepV_0977	Mirtazapine	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.19 %)	Approved	27476412
DrugRepV_0978	Formoterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.97 %)	Approved, Investigational	27476412
DrugRepV_0979	Ticlopidine Hydrochloride	Blood and Blood Forming Organs	Stroke	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.53 %)	Approved	27476412
DrugRepV_0980	Zoledronic Acid Monohydrate	Musculo-Skeletal System	Hypercalcemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.625 %)	Approved	27476412
DrugRepV_0981	Aminophylline	Respiratory System	Asthma, bronchospasm and Chronic Obstructive Pulmonary Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.325 %)	Approved	27476412
DrugRepV_0982	Cefixime	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.925 %)	Approved	27476412
DrugRepV_0983	Buspirone Hydrochloride	Nervous System	Anxiety and depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.19 %)	Approved	27476412
DrugRepV_0984	Warfarin Sodium	Blood and Blood Forming Organs	Coagulation disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.055 %)	Approved	27476412
DrugRepV_0985	Mestranol	NA	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.56 %)	Approved	27476412
DrugRepV_0986	Pyrazinamide	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.975 %)	Approved, Investigational	27476412
DrugRepV_0987	Epinastine Hydrochloride	Sensory Organ	Allergy and conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.33 %)	Approved	27476412
DrugRepV_0988	Pyridostigmine Bromide	Nervous System	Myasthenia gravis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.965 %)	Approved, Investigational	27476412
DrugRepV_0989	Ursodiol	NA	Gallstone and cholestatic forms of liver diseases including primary biliary cirrhosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.78 %)	Approved	27476412
DrugRepV_0990	Ibuprofen	Musculo-Skeletal System	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.025 %)	Approved	27476412
DrugRepV_0991	Sodium Phenylbutyrate	Alimentary Tract and Metabolism	Chronic urea cycle disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.64 %)	Approved	27476412
DrugRepV_0992	Glycopyrrolate Iodide	Alimentary Tract And Metabolism; Respiratory System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.585 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0993	Clotrimazole	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.76 %)	Approved	27476412
DrugRepV_0994	Chlorpheniramine Maleate	Respiratory System	Rhinitis, urticaria, allergy, common cold, asthma and hay fever	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.605 %)	Approved	27476412
DrugRepV_0995	Trientine Dihydrochloride	Alimentary Tract and Metabolism	Wilson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.41 %)	Approved	27476412
DrugRepV_0996	Cinacalcet Hydrochloride	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperparathyroidism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.525 %)	Approved	27476412
DrugRepV_0997	Metaxalone	NA	Musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.445 %)	Approved	27476412
DrugRepV_0998	Carbamazepine	Nervous System	Epilepsy and pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.68 %)	Approved	27476412
DrugRepV_0999	Dofetilide	Cardiovascular agents	Atrial flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.755 %)	Approved	27476412
DrugRepV_1000	Beclomethasone Dipropionate	NA	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.25 %)	Approved	27476412
DrugRepV_1001	Delavirdine Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.035 %)	Approved	27476412
DrugRepV_1002	Balsalazide	Alimentary Tract and Metabolism	Active ulcerative colitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.825 %)	Approved	27476412
DrugRepV_1003	Carvedilol	Cardiovascular agents	Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.625 %)	Approved	27476412
DrugRepV_1004	Estramustine phosphate Sodium	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.96 %)	Approved	27476412
DrugRepV_1005	Goserelin Acetate	Antineoplastic and Immunomodulating Agents	Prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.315 %)	Approved	27476412
DrugRepV_1006	Bimatoprost	Sensory Organ	Ocular Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.62 %)	Approved	27476412
DrugRepV_1007	Phenelzine Sulfate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.225 %)	Approved	27476412
DrugRepV_1008	Disulfiram	Nervous System	Chronic alcoholism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.105 %)	Approved	27476412
DrugRepV_1009	Olmesartan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.095 %)	Approved, Investigational	27476412
DrugRepV_1010	Lidocaine Hydrochloride Hydrate	Cardiovascular agents	Anesthesia | Ventricular arrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.62 %)	Approved, Vet approved	27476412
DrugRepV_1011	Pemetrexed Disodium	Antineoplastic and Immunomodulating Agents	Cancer (Chemotherapy drug) | Malignant pleural mesothelioma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.02 %)	Approved, Investigational	27476412
DrugRepV_1012	Cefaclor	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.11 %)	Approved	27476412
DrugRepV_1013	Vardenafil	Genito Urinary System and Sex Hormones	Erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.67 %)	Approved	27476412
DrugRepV_1014	Fulvestrant	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.615 %)	Approved, Investigational	27476412
DrugRepV_1015	Chloramphenicol	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.08 %)	Approved	27476412
DrugRepV_1016	Spironolactone	Cardiovascular agents	Heart failure | Hyperaldosteronism | Adrenal hyperplasia | Hypertension | Nephrotic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.965 %)	Approved	27476412
DrugRepV_1017	Ranitidine Hydrochloride	Alimentary Tract and Metabolism	Duodenal ulcer | Pathological hypersecretion of gastric acid | Gastric ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.44 %)	Approved, Withdrawn	27476412
DrugRepV_1018	Caffeine	Nervous System	Fatigue, orthostatic hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.37 %)	Approved	27476412
DrugRepV_1019	Tolmetin Sodium Dihydrate	Musculo-Skeletal System	Rheumatoid arthritis and osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.77 %)	Approved	27476412
DrugRepV_1020	Cidofovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.06 %)	Approved	27476412
DrugRepV_1021	Levofloxacin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (Conjunctivitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.885 %)	Approved	27476412
DrugRepV_1022	Demeclocycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.41 %)	Approved	27476412
DrugRepV_1023	Tolbutamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.45 %)	Approved, Investigational	27476412
DrugRepV_1024	Arsenic Trioxide	Antineoplastic and Immunomodulating Agents	Acute promyelocytic leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.425 %)	Approved	27476412
DrugRepV_1025	Pancuronium Dibromide	Musculo-Skeletal System	Muscle relaxant during anesthesia and surgical procedures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.955 %)	Approved	27476412
DrugRepV_1026	Cefuroxime Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.005 %)	Approved	27476412
DrugRepV_1027	Ibutilide Fumarate	Cardiovascular agents	Atrial flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.475 %)	Approved	27476412
DrugRepV_1028	Guanabenz Acetate	Cardiovascular agents	High blood pressure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.815 %)	Approved	27476412
DrugRepV_1029	Ethambutol Dihydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.32 %)	Approved	27476412
DrugRepV_1030	Bisacodyl	Alimentary Tract and Metabolism	Colon cleansing	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.3 %)	Approved	27476412
DrugRepV_1031	Thalidomide	Antineoplastic and Immunomodulating Agents	Erythema nodosum leprosum	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.365 %)	Approved, Investigational, Withdrawn	27476412
DrugRepV_1032	Alfuzosin	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.7 %)	Approved	27476412
DrugRepV_1033	Zileuton	NA	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.355 %)	Approved, Withdrawn	27476412
DrugRepV_1034	Lacosamide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.055 %)	Approved	27476412
DrugRepV_1035	Doxycycline Monohydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.935 %)	Approved	27476412
DrugRepV_1036	Dacarbazine	Antineoplastic and Immunomodulating Agents	Hodgkin disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.515 %)	Approved	27476412
DrugRepV_1037	Dyphylline	Respiratory System	Chronic bronchitis and emphysema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.825 %)	Approved	27476412
DrugRepV_1038	Rasagiline Mesylate	Nervous System	Idiopathic Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.31 %)	Approved	27476412
DrugRepV_1039	Tiludronate Disodium	NA	Paget disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.63 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1040	Chloroquine Diphosphate	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.115 %)	Approved	27476412
DrugRepV_1041	Floxuridine	Anticancer	Gastrointestinal adenocarcinomas	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.32 %)	Approved	27476412
DrugRepV_1042	Ergotamine Tartrate	Nervous System	Vascular headache	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.33 %)	Approved	27476412
DrugRepV_1043	Voriconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.235 %)	Approved	27476412
DrugRepV_1044	Clonidine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.37 %)	Approved	27476412
DrugRepV_1045	Dapsone	Antiinfectives For Systemic Use	Leprosy and dermatitis herpetiformis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.585 %)	Approved	27476412
DrugRepV_1046	Rivastigmine Tartrate	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.655 %)	Approved, Investigational	27476412
DrugRepV_1047	Ezetimibe	Cardiovascular agents	Hyperlipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.62 %)	Approved	27476412
DrugRepV_1048	Azelaic acid	Dermatologicals	Acne vulgaris	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.95 %)	Approved	27476412
DrugRepV_1049	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.075 %)	Approved	27476412
DrugRepV_1050	Aminohippurate Sodium	Various	Measure effective renal plasma flow	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.04 %)	Approved	27476412
DrugRepV_1051	Bupivacaine Hydrochloride	Nervous System	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.995 %)	Approved	27476412
DrugRepV_1052	Dipyridamole	Blood and Blood Forming Organs	Coagulation disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.91 %)	Approved	27476412
DrugRepV_1053	Bacitracin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.205 %)	Approved	27476412
DrugRepV_1054	Dienogest	Genito Urinary System and Sex Hormones	Endometriosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.265 %)	Approved	27476412
DrugRepV_1055	Ceftizoxim Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.58 %)	Approved	27476412
DrugRepV_1056	Ethosuximide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.245 %)	Approved	27476412
DrugRepV_1057	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.74 %)	Approved	27476412
DrugRepV_1058	Proparacaine Hydrochloride	Sensory Organ	Ophthalmic anesthetic	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.315 %)	Approved, Vet approved	27476412
DrugRepV_1059	Mepivacaine Hydrochloride	Nervous System	Analgesia | Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.64 %)	Approved, Vet approved	27476412
DrugRepV_1060	Amiloride Hydrochloride Dihydrate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.595 %)	Approved	27476412
DrugRepV_1061	Methsuximide	Anticonvulsant	Seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.81 %)	Approved	27476412
DrugRepV_1062	Acamprosate	Nervous System	Alcohol dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.895 %)	Approved	27476412
DrugRepV_1063	Estrone	Genito Urinary System and Sex Hormones	Perimenopausal and postmenopausal symptoms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.96 %)	Approved	27476412
DrugRepV_1064	Glipizide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.385 %)	Approved, Investigational	27476412
DrugRepV_1065	Nateglinide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.745 %)	Approved, Investigational	27476412
DrugRepV_1066	Lomustine	Antineoplastic and Immunomodulating Agents	Brain tumor	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.175 %)	Approved, Investigational	27476412
DrugRepV_1067	Midodrine Hydrochloride	NA	Orthostatic Hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.235 %)	Approved	27476412
DrugRepV_1068	Norepinephrine Bitartrate Monohydrate	Cardiovascular agents	Vasodilatory shock states such as septic shock and neurogenic shock | Vasopressor medication for patients with critical hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.87 %)	Approved	27476412
DrugRepV_1069	Aripiprazole	Nervous System	Schizophrenia and psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.35 %)	Approved	27476412
DrugRepV_1070	Terazosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.235 %)	Approved	27476412
DrugRepV_1071	Fenoprofen Calcium	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.89 %)	Approved	27476412
DrugRepV_1072	Miglitol	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.84 %)	Approved	27476412
DrugRepV_1073	Methscopolamine Bromide	Alimentary Tract And Metabolism; Sensory Organ	Peptic ulcers | Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.49 %)	Approved	27476412
DrugRepV_1074	Riluzole Hydrochloride	Nervous System	Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.545 %)	Approved, Investigational	27476412
DrugRepV_1075	Cefotaxime Acid	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.85 %)	Approved	27476412
DrugRepV_1076	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55 %)	Approved	27476412
DrugRepV_1077	Rosuvastatin Calcium	Cardiovascular agents	Hyperlipidemia | Dyslipidemia | Hypertriglyceridemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.215 %)	Approved	27476412
DrugRepV_1078	Clindamycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.415 %)	Approved	27476412
DrugRepV_1079	Sitagliptin Phosphate	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.02 %)	Approved, Investigational	27476412
DrugRepV_1080	Pentostatin	Antineoplastic and Immunomodulating Agents	Hairy cell leukaemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.995 %)	Approved, Investigational	27476412
DrugRepV_1081	Labetalol Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.74 %)	Approved	27476412
DrugRepV_1082	Tiopronin	Genito Urinary System and Sex Hormones	Kidney stone	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.93 %)	Approved	27476412
DrugRepV_1083	Eflornithine Hydrochloride	Dermatologicals	Facial hirsutism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.285 %)	Approved, Withdrawn	27476412
DrugRepV_1084	Gemifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Chronic bronchitis and mild-to-moderate pneumonia)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.92 %)	Approved, Investigational	27476412
DrugRepV_1085	Adefovir dipivoxil	Antiinfectives For Systemic Use	Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.3 %)	Approved	27476412
DrugRepV_1086	Doxapram Hydrochloride Hydrate	Respiratory System	Obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.45 %)	Approved	27476412
DrugRepV_1087	Cetirizine Hydrochloride	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.565 %)	Approved	27476412
DrugRepV_1088	Methyclothiazide	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.82 %)	Approved	27476412
DrugRepV_1089	Ceftazidime	Antibacterial	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.255 %)	Approved	27476412
DrugRepV_1090	Cefprozil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.765 %)	Approved	27476412
DrugRepV_1091	Ipratropium bromide	Respiratory System	Asthma | Chronic bronchitis | Emphysema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.345 %)	Approved, Experimental	27476412
DrugRepV_1092	Colistin Sulfate	Alimentary Tract and Metabolism	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.875 %)	Approved	27476412
DrugRepV_1093	Daunorubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (72.65 %)	Approved	27476412
DrugRepV_1094	Succinylcholine Chloride Dihydrate	Musculo-Skeletal System	Muscle spasms (Muscle Relaxant)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.005 %)	Approved	27476412
DrugRepV_1095	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.065 %)	Approved	27476412
DrugRepV_1096	Cefdinir	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.845 %)	Approved	27476412
DrugRepV_1097	Tropicamide	Sensory Organ	Mydriasis and Cycloplegia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.195 %)	Approved	27476412
DrugRepV_1098	Entacapone	Nervous System	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.01 %)	Approved	27476412
DrugRepV_1099	Cisplatin	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.65 %)	Approved	27476412
DrugRepV_1100	Acetylcholine Chloride	Sensory Organ	Ophthalmological Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.43 %)	Approved	27476412
DrugRepV_1101	Ketoprofen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Dysmenorrhea | Pain (sprains and strains, postoperative (including dental surgery) or postpartum pain)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.115 %)	Approved, Vet approved	27476412
DrugRepV_1102	Paromomycin Sulfate	Alimentary Tract and Metabolism	Intestinal Amebiasis | Hepatic coma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.015 %)	Approved	27476412
DrugRepV_1103	Cycloserine	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.77 %)	Approved	27476412
DrugRepV_1104	Norethindrone	Gynaecological-agents	Secondary amenorrhea | Endometriosis | Abnormal uterine bleeding	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.75 %)	Approved	27476412
DrugRepV_1105	Flumazenil	Various	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.315 %)	Approved	27476412
DrugRepV_1106	Quetiapine Fumarate	Nervous System	Schizophrenia | Bipolar disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.45 %)	Approved	27476412
DrugRepV_1107	Finasteride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.37 %)	Approved	27476412
DrugRepV_1108	Trimethadione	Nervous System	Seizure | Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.375 %)	Approved	27476412
DrugRepV_1109	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.855 %)	Approved, Investigational	27476412
DrugRepV_1110	Pentoxifylline	Cardiovascular agents	Chronic occlusive arterial disease of the limbs	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.155 %)	Approved, Investigational	27476412
DrugRepV_1111	Moxifloxacin Hydrochloride	Antiinfectives For Systemic Use	Sinusitis | Pneumonia | Chronic bronchitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.71 %)	Approved, Investigational	27476412
DrugRepV_1112	Capsaicin	Nervous System	Neuropathic pain associated with post-herpetic neuralgia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.63 %)	Approved	27476412
DrugRepV_1113	Oxytetracycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.71 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1114	Zafirlukast	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.94 %)	Approved	27476412
DrugRepV_1115	Niacin	NA	Hyperlipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.67 %)	Approved, Investigational, Nutraceutical	27476412
DrugRepV_1116	Valganciclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.32 %)	Approved	27476412
DrugRepV_1117	Losartan Potassium	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.79 %)	Approved	27476412
DrugRepV_1118	4-Aminosalicylic Acid	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.44 %)	Approved	27476412
DrugRepV_1119	Butenafine Hydrochloride	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.54 %)	Approved	27476412
DrugRepV_1120	Nisoldipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.255 %)	Approved	27476412
DrugRepV_1121	Dobutamine Hydrochloride	Cardiovascular agents	Cardiovascular disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.705 %)	Approved	27476412
DrugRepV_1122	Vigabatrin	Nervous System	Epilepsy and Seizure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.795 %)	Approved	27476412
DrugRepV_1123	Flunisolide	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.785 %)	Approved, Investigational	27476412
DrugRepV_1124	Mafenide Hydrochloride	Dermatologicals	Severe burns	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.525 %)	Approved, Vet approved	27476412
DrugRepV_1125	Levalbuterol Hydrochloride	Respiratory System	Chronic obstructive pulmonary disease | Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.305 %)	Approved, Investigational	27476412
DrugRepV_1126	Milnacipran Hydrochloride	Nervous System	Depressive disorder | Fibromyalgia pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.375 %)	Approved, Investigational	27476412
DrugRepV_1127	Droperidol	Nervous System	Nausea and vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.61 %)	Approved	27476412
DrugRepV_1128	Ramelteon	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.02 %)	Approved, Investigational	27476412
DrugRepV_1129	Fluorometholone	Sensory Organ	Inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.275 %)	Approved, Investigational	27476412
DrugRepV_1130	Ketorolac Tromethamine	Musculo-Skeletal System	Osteoarthritis | Severe Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.06 %)	Approved	27476412
DrugRepV_1131	Methenamine Hippurate	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.645 %)	Approved, Vet approved	27476412
DrugRepV_1132	Cloxacillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.82 %)	Approved	27476412
DrugRepV_1133	Candesartan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.62 %)	Experimental	27476412
DrugRepV_1134	Disopyramide	Cardiovascular agents	Ventricular tachycardia and arrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.605 %)	Approved	27476412
DrugRepV_1135	Fluocinonide	Dermatologicals	Eczema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.945 %)	Approved, Investigational	27476412
DrugRepV_1136	Sotalol Hydrochloride	Cardiovascular agents	Atrial flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.965 %)	Approved	27476412
DrugRepV_1137	Fenofibrate	Cardiovascular agents	Hypercholesterolemia | Dyslipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.755 %)	Approved	27476412
DrugRepV_1138	Travoprost	Sensory Organ	Glaucoma or ocular hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.805 %)	Approved	27476412
DrugRepV_1139	Medroxyprogesterone Acetate	Genito Urinary System and Sex Hormones	Amenorrhea | Abnormal uterine bleeding	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.06 %)	Approved	27476412
DrugRepV_1140	Clozapine	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.96 %)	Approved	27476412
DrugRepV_1141	Torsemide	Cardiovascular agents	Edema and hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.19 %)	Approved	27476412
DrugRepV_1142	Decitabine	Antineoplastic and Immunomodulating Agents	Myelodysplastic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.315 %)	Approved	27476412
DrugRepV_1143	Metoprolol Tartrate	Cardiovascular agents	Angina | Heart failure | Myocardial infarction | Atrial fibrillation | Atrial flutter | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.545 %)	Approved, Investigational	27476412
DrugRepV_1144	Dexchlorpheniramine Maleate	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.11 %)	Approved	27476412
DrugRepV_1145	Fludrocortisone Acetate	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Addison disease and salt-losing adrenogenital syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.635 %)	Approved	27476412
DrugRepV_1146	Cyclopentolate	Sensory Organ	Mydriasis and cycloplegia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.525 %)	Approved	27476412
DrugRepV_1147	Tirofiban Hydrochloride	Blood and Blood Forming Organs	Acute coronary syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.245 %)	Approved	27476412
DrugRepV_1148	Piperacillin	Antiinfectives For Systemic Use	Polymicrobial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.9 %)	Approved	27476412
DrugRepV_1149	Rizatriptan Benzoate	NA	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.98 %)	Approved	27476412
DrugRepV_1150	Diflunisal	Nervous System	Osteoarthritis and rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.05 %)	Approved	27476412
DrugRepV_1151	Famciclovir	Antiinfectives For Systemic Use	Herpes simplex virus | Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.62 %)	Approved, Investigational	27476412
DrugRepV_1152	Metyrapone	Various	Cushing syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.775 %)	Approved, Investigational	27476412
DrugRepV_1153	Naphazoline Hydrochloride	Respiratory System; Sensory Organ	Eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.32 %)	Approved, Investigational	27476412
DrugRepV_1154	Quinapril Hydrochloride	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.015 %)	Approved, Investigational	27476412
DrugRepV_1155	Levobunolol Hydrochloride	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.12 %)	Approved	27476412
DrugRepV_1156	Metolazone	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.57 %)	Approved	27476412
DrugRepV_1157	Amoxicillin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.335 %)	Approved	27476412
DrugRepV_1158	Testosterone Enanthate	Genito Urinary System and Sex Hormones	Primary hypogonadism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.075 %)	Approved	27476412
DrugRepV_1159	Esomeprazole Potassium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.98 %)	Approved	27476412
DrugRepV_1160	Anastrozole	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.01 %)	Approved	27476412
DrugRepV_1161	Pemirolast Potassium	Respiratory-Tract-agents	Eye itching caused by allergies such as hay fever, and allergic conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.52 %)	Approved	27476412
DrugRepV_1162	Flurandrenolide	Dermatologicals	Skin disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.98 %)	Approved	27476412
DrugRepV_1163	Sulfanilamide	Antiinfectives For Systemic Use	Vulvovaginitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.175 %)	Approved	27476412
DrugRepV_1164	Memantine Hydrochloride	Nervous System	Alzheimer's dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.785 %)	Approved, Investigational	27476412
DrugRepV_1165	Rifampin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.505 %)	Approved	27476412
DrugRepV_1166	Repaglinide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.1 %)	Approved, Investigational	27476412
DrugRepV_1167	Cefepime Hydrochloride Hydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.89 %)	Approved	27476412
DrugRepV_1168	Ropivacaine Hydrochloride Monohydrate	Nervous System	Used in obstetric anesthesia and regional anesthesia for surgery	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.655 %)	Approved	27476412
DrugRepV_1169	Orlistat	Alimentary Tract and Metabolism	Obesity	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.835 %)	Approved, Investigational	27476412
DrugRepV_1170	Oxaprozin	Musculo-Skeletal System	Inflammation | Swelling | Stiffness | Joint pain associated with rheumatoid arthritis and osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.255 %)	Approved	27476412
DrugRepV_1171	Naftifine Hydrochloride	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.795 %)	Approved	27476412
DrugRepV_1172	Phenylephrine	Cardiovascular agents; Respiratory System; Sensory Organ	Nasal congestion | Hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.085 %)	Approved	27476412
DrugRepV_1173	Oxiconazole Nitrate	Dermatologicals	Dermal fungal infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.345 %)	Approved	27476412
DrugRepV_1174	Chlorpromazine Hydrochloride	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.955 %)	Approved	27476412
DrugRepV_1175	Nicotine	Nervous System	Nicotine dependence (Tobacco smoke)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.33 %)	Approved	27476412
DrugRepV_1176	Trandolapril	Cardiovascular agents	Hypertension and Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.025 %)	Approved	27476412
DrugRepV_1177	Doripenem	Antiinfectives For Systemic Use	Intra-abdominal infections and complicated urinary tract infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.47 %)	Approved	27476412
DrugRepV_1178	Phenoxybenzamine Hydrochloride	Cardiovascular agents	Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.895 %)	Approved	27476412
DrugRepV_1179	Amiodarone Hydrochloride	Cardiovascular agents	Anginal and Arrhythmia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.055 %)	Approved	27476412
DrugRepV_1180	Topiramate	Nervous System	Seizures (Epilepsy) | Migraine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.995 %)	Approved	27476412
DrugRepV_1181	Brimonidine	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.265 %)	Approved	27476412
DrugRepV_1182	Methylprednisolone	Dermatologicals; Dermatologicals; Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.3 %)	Approved, Vet approved	27476412
DrugRepV_1183	Flavoxate Hydrochloride	Genito Urinary System and Sex Hormones	Urinary syndromes	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.38 %)	Approved	27476412
DrugRepV_1184	Propofol	Nervous System	Anaesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.53 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1185	Isosorbide Dinitrate	Cardiovascular agents	Angina pectoris (Coronary artery disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.66 %)	Approved, Investigational	27476412
DrugRepV_1186	Mannitol	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; and Respiratory System	Diuresis | Intracranial pressure | Cerebral edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.355 %)	Approved, Investigational	27476412
DrugRepV_1187	Cefadroxil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.15 %)	Approved	27476412
DrugRepV_1188	Lindane	Antiparasitic products, Insectisides and Repellents	Scabies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.465 %)	Approved, Withdrawn	27476412
DrugRepV_1189	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.03 %)	Approved	27476412
DrugRepV_1190	Ranolazine Dihydrochloride	Cardiovascular agents	Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.88 %)	Approved	27476412
DrugRepV_1191	Dicloxacillin Sodium Salt Monohydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.765 %)	Approved	27476412
DrugRepV_1192	Etidronate Disodium	Musculo-Skeletal System	Paget disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.165 %)	Approved	27476412
DrugRepV_1193	Carbidopa	Neurologic-agent	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.045 %)	Approved	27476412
DrugRepV_1194	Cimetidine	Alimentary Tract and Metabolism	Peptic ulcers, heartburn and acid indigestion	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.79 %)	Approved	27476412
DrugRepV_1195	Dalfampridine	Nervous System	Multiple sclerosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.235 %)	Approved	27476412
DrugRepV_1196	Ganciclovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.48 %)	Approved, Investigational	27476412
DrugRepV_1197	Tiagabine Hydrochloride	Nervous System	Panic disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.68 %)	Approved, Investigational	27476412
DrugRepV_1198	Trihexyphenidyl Hydrochloride	Nervous System	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.61 %)	Approved	27476412
DrugRepV_1199	Rifaximin	Alimentary Tract and Metabolism	Traveller's Diarrhea | Irritable bowel syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.745 %)	Approved, Investigational	27476412
DrugRepV_1200	Fosphenytoin Sodium Pentahydrate	Nervous System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.9 %)	Approved, Investigational	27476412
DrugRepV_1201	Aspirin	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; and Nervous System	Rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.71 %)	Approved	27476412
DrugRepV_1202	Flutamide	Antineoplastic and Immunomodulating Agents	Prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.23 %)	Approved, Investigational	27476412
DrugRepV_1203	Meloxicam	Musculo-Skeletal System	Arthritis | Osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.475 %)	Approved, Vet approved	27476412
DrugRepV_1204	Amlexanox	Respiratory System	Asthma and rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.71 %)	Approved	27476412
DrugRepV_1205	Naringenin	NA	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.34 %)	Experimental	27476412
DrugRepV_1206	Lansoprazole	Alimentary Tract and Metabolism	Gastric acid secretion | Gastric ulcers, active duodenal ulcers | Erosive reflux oesophagitis | Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.545 %)	Approved, Investigational	27476412
DrugRepV_1207	(S)-Timolol Maleate	Cardiovascular agents; Sensory	Hypertension, heart disease and anginal pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.365 %)	Approved	27476412
DrugRepV_1208	Regadenoson	Cardiovascular agents	Myocardial perfusion imaging (MPI)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.46 %)	Approved	27476412
DrugRepV_1209	Maraviroc	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.18 %)	Approved, Investigational	27476412
DrugRepV_1210	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.73 %)	Approved	27476412
DrugRepV_1211	Ifosfamide	Antineoplastic and Immunomodulating Agents	Germ cell testicular cancer | Cervical cancer | Osteosarcoma | Bladder cancer | Ovarian cancer | Small cell lung cancer | Non-Hodgkin's lymphoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.825 %)	Approved	27476412
DrugRepV_1212	Zalcitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.06 %)	Approved	27476412
DrugRepV_1213	Cyclophosphamide Monohydrate	Antineoplastic and Immunomodulating Agents	Lymphoma and leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.745 %)	Approved	27476412
DrugRepV_1214	Sildenafil Citrate	Genito Urinary System and Sex Hormones	Erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.095 %)	Approved, Investigational	27476412
DrugRepV_1215	Metronidazole	Antiparasitic products, Insectisides and Repellents	Amebiasis | Vaginitis | Trichomonas infections | Giardiasis | Anaerobic bacteria | Treponemal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.465 %)	Approved	27476412
DrugRepV_1216	Kanamycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.43 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1217	Clomipramine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.19 %)	Approved	27476412
DrugRepV_1218	Methocarbamol	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.16 %)	Approved, Vet approved	27476412
DrugRepV_1219	Methimazole	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperthyroidism | Goiter | Graves disease | Psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.56 %)	Approved	27476412
DrugRepV_1220	Amcinonide	Dermatologicals	Inflammatory and pruritic	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.13 %)	Approved	27476412
DrugRepV_1221	Aminolevulinic Acid Hydrochloride	Antineoplastic and Immunomodulating Agents	Actinic keratosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.19 %)	Approved	27476412
DrugRepV_1222	Betaxolol Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.605 %)	Approved	27476412
DrugRepV_1223	Metformin Hydrochloride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.215 %)	Approved	27476412
DrugRepV_1224	Galantamine Hydrobromide	NA	Alzheimer's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.96 %)	Approved	27476412
DrugRepV_1225	Nevirapine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.07 %)	Approved	27476412
DrugRepV_1226	Pindolol	Cardiovascular agents	Hypertension | Edema | Ventricular tachycardias | Atrial fibrillation	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.37 %)	Approved, Investigational	27476412
DrugRepV_1227	Darunavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.605 %)	Approved	27476412
DrugRepV_1228	Sulfacetamide Sodium	Dermatologicals	Bacterial infections (Vaginitis, keratitis, acute conjunctivitis, and blepharitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.36 %)	Approved	27476412
DrugRepV_1229	Nalbuphine Hydrochloride Dihydrate	Nervous System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.375 %)	Approved	27476412
DrugRepV_1230	Temozolomide	Antineoplastic and Immunomodulating Agents	Anaplastic astrocytoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.52 %)	Approved	27476412
DrugRepV_1231	Azelastine Hydrochloride	Respiratory System	Rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.96 %)	Approved	27476412
DrugRepV_1232	Busulfan	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.405 %)	Approved	27476412
DrugRepV_1233	Methylergonovine Maleate	Genito Urinary System and Sex Hormones	Postpartum hemorrhage	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.715 %)	Approved	27476412
DrugRepV_1234	Cefotetan Disodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.645 %)	Approved	27476412
DrugRepV_1235	Aztreonam	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.05 %)	Approved	27476412
DrugRepV_1236	Phentolamine Hydrochloride	Cardiovascular agents	Pheochromocytoma | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.465 %)	Approved	27476412
DrugRepV_1237	Salbutamol Hemisulfate	Respiratory System	Bronchial asthma | Chronic bronchitis | Chronic bronchopulmonary disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.66 %)	Approved	27476412
DrugRepV_1238	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.75 %)	Approved, Investigational	27476412
DrugRepV_1239	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.36 %)	Approved	27476412
DrugRepV_1240	Drospirenone	Genito Urinary System and Sex Hormones	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.33 %)	Approved	27476412
DrugRepV_1241	Malathion	Antiparasitic products, Insectisides and Repellents	Pediculus humanus capitis of the scalp hair	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.575 %)	Approved, Investigational	27476412
DrugRepV_1242	Captopril	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.42 %)	Approved	27476412
DrugRepV_1243	Fluorouracil	Antineoplastic and Immunomodulating Agents	Multiple actinic or solar keratoses | Cancer, such as colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.195 %)	Approved	27476412
DrugRepV_1244	Propylthiouracil	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperthyroidism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.32 %)	Approved, Investigational	27476412
DrugRepV_1245	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.175 %)	Approved	27476412
DrugRepV_1246	Tranexamic Acid	Blood and Blood Forming Organs	Hemorrhage	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.975 %)	Approved	27476412
DrugRepV_1247	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.405 %)	Approved, Investigational	27476412
DrugRepV_1248	Atracurium Besylate	Musculo-Skeletal System	Endotracheal intubation	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.525 %)	Approved	27476412
DrugRepV_1249	Dorzolamide Hydrochloride	Sensory Organ	Open-angle glaucoma and ocular hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.595 %)	Approved	27476412
DrugRepV_1250	Cefoxitin Sodium	Antibiotics	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.11 %)	Approved	27476412
DrugRepV_1251	Isotretinoin	Dermatologicals	Acne	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.065 %)	Approved	27476412
DrugRepV_1252	Griseofulvin	Dermatologicals	Fungal infections (Ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.7 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1253	Dihydroergotamine Mesylate	Nervous System	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.92 %)	Approved	27476412
DrugRepV_1254	Theophylline	Respiratory System	Chronic asthma | Chronic lung diseases, such as emphysema and chronic bronchitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.835 %)	Approved	27476412
DrugRepV_1255	Alprostadil	Genito Urinary System and Sex Hormones	Palliative and erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.655 %)	Approved	27476412
DrugRepV_1256	Diatrizoate Meglumine	Various	X-ray contrast medium, gastrointestinal studies, angiography, and urography	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.205 %)	Approved	27476412
DrugRepV_1257	Streptozocin	Antineoplastic and Immunomodulating Agents	Malignant neoplasms of pancreas (metastatic islet cell carcinoma)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.225 %)	Approved, Investigational	27476412
DrugRepV_1258	Ropinirole Hydrochloride	Nervous System	Parkinson's disease | Restless legs syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.565 %)	Approved, Investigational	27476412
DrugRepV_1259	Nicardipine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.09 %)	Approved, Investigational	27476412
DrugRepV_1260	Silver Sulfadiazine	Dermatologicals	Wound sepsis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.965 %)	Approved	27476412
DrugRepV_1261	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.915 %)	Approved, Investigational	27476412
DrugRepV_1262	Cefditoren Pivoxil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.4 %)	Approved	27476412
DrugRepV_1263	Disodium Cromoglycate	Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System; Sensory Or	Allergy and asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.03 %)	Approved	27476412
DrugRepV_1264	Cefpodoxime Proxetil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.81 %)	Approved	27476412
DrugRepV_1265	Baclofen	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.605 %)	Approved	27476412
DrugRepV_1266	Miglustat	Alimentary Tract and Metabolism	Gaucher's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.98 %)	Approved	27476412
DrugRepV_1267	Selegiline Hydrochloride	Nervous System	Parkinson's Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.86 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1268	Guanidine Hydrochloride	Musculo-Skeletal System	Muscle weakness | Myasthenic syndrome of Eaton-Lambert	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.91 %)	Approved	27476412
DrugRepV_1269	Carglumic Acid	NA	Hyperammonaemia in patients with N-acetylglutamate synthase (NAGS) deficiency	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.855 %)	Approved	27476412
DrugRepV_1270	Flecainide Acetate	Cardiovascular agents	Arrhythmia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.52 %)	Approved, Withdrawn	27476412
DrugRepV_1271	Meropenem	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.025 %)	Approved, Investigational	27476412
DrugRepV_1272	Milrinone	Cardiovascular agents	Cardiotonic agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.26 %)	Approved	27476412
DrugRepV_1273	Bromfenac	Sensory Organ	Non-steroidal anti-inflammatory agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.755 %)	Approved	27476412
DrugRepV_1274	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.2 %)	Approved, Investigational	27476412
DrugRepV_1275	Citalopram Hydrobromide	Nervous System	Depressive disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.045 %)	Approved	27476412
DrugRepV_1276	Tigecycline	Antiinfectives For Systemic Use	Complicated skin and skin structure infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.4 %)	Approved	27476412
DrugRepV_1277	Naratriptan Hydrochloride	Nervous System	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.13 %)	Approved, Investigational	27476412
DrugRepV_1278	Latanoprost	Sensory Organ	Glaucoma or ocular hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.57 %)	Approved, Investigational	27476412
DrugRepV_1279	Dopamine Hydrochloride	Cardiovascular agents	Arrythmias and arterial hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.74 %)	Approved	27476412
DrugRepV_1280	Brompheniramine Maleate	Respiratory System	Allergies, rhinitis and urticaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.015 %)	Approved	27476412
DrugRepV_1281	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.09 %)	Approved	27476412
DrugRepV_1282	Fosfomycin Calcium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.385 %)	Approved	27476412
DrugRepV_1283	Zolmitriptan	Nervous System	Migraine with or without auras	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.49 %)	Approved	27476412
DrugRepV_1284	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.76 %)	Approved	27476412
DrugRepV_1285	Carbinoxamine maleate	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.11 %)	Approved	27476412
DrugRepV_1286	Hydroxocobalamin Hydrochloride	Blood and Blood Forming Organs	Vitamin B12 deficiency	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.41 %)	Approved	27476412
DrugRepV_1287	Bicalutamide	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.37 %)	Approved	27476412
DrugRepV_1288	Trimethoprim	Antiinfectives For Systemic Use	Urinary tract infections | Uncomplicated pyelonephritis (with sulfamethoxazole) | Mild acute prostatitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.69 %)	Approved	27476412
DrugRepV_1289	Mefenamic Acid	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Dysmenorrhea, and mild to moderate pain, inflammation, and fever	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.43 %)	Approved	27476412
DrugRepV_1290	Gentamycin Sulfate	NA	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.715 %)	Approved	27476412
DrugRepV_1291	Olanzapine	Nervous System	Schizophrenia | Bipolar I disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.535 %)	Approved, Investigational	27476412
DrugRepV_1292	Argatroban	Blood and Blood Forming Organs	Coagulation disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.59 %)	Approved	27476412
DrugRepV_1293	Trimethobenzamide Hydrochloride	Respiratory System	Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.125 %)	Approved, Investigational	27476412
DrugRepV_1294	Pramipexole Dihydrochloride Monohydrate	Nervous System	Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.46 %)	Approved, Investigational	27476412
DrugRepV_1295	Cilastatin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.065 %)	Approved	27476412
DrugRepV_1296	Levocetirizine Dihydrochloride	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.885 %)	Approved	27476412
DrugRepV_1297	Naloxone Hydrochloride	Alimentary Tract And Metabolism; Various	Narcotic depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.38 %)	Approved, Vet approved	27476412
DrugRepV_1298	Hydroxyurea	Antineoplastic and Immunomodulating Agents	Melanoma | Chronic myelocytic leukemia | Ovary carcinoma | Sickle-cell anemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.375 %)	Approved	27476412
DrugRepV_1299	Vecuronium bromide	Musculo-Skeletal System	Non-depolarizing neuromuscular blocking agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.6 %)	Approved	27476412
DrugRepV_1300	Paliperidone	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.455 %)	Approved	27476412
DrugRepV_1301	Glimepiride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.29 %)	Approved	27476412
DrugRepV_1302	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.29 %)	Approved, Investigational	27476412
DrugRepV_1303	Piroxicam	Musculo-Skeletal System	Osteoarthritis | Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.81 %)	Approved, Investigational	27476412
DrugRepV_1304	Ramipril	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.37 %)	Approved	27476412
DrugRepV_1305	Bisoprolol Fumarate	Cardiovascular agents	Cardiovascular disease, angina pectoris and myocardial infarction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.34 %)	Approved	27476412
DrugRepV_1306	Dinoprostone	Genito Urinary System and Sex Hormones	Gestational trophoblastic disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.46 %)	Approved	27476412
DrugRepV_1307	Neomycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.33 %)	Approved	27476412
DrugRepV_1308	Penicillamine	Musculo-Skeletal System	Wilson disease | Cystinuria | Active rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.665 %)	Approved	27476412
DrugRepV_1309	Nafcillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.57 %)	Approved, Investigational	27476412
DrugRepV_1310	Capreomycin Disulfate	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.425 %)	Approved	27476412
DrugRepV_1311	Mupirocin	Dermatologicals and Respiratory System	Impetigo | Skin lesions (Staphylococci infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.04 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1312	Cefazolin Sodium	Antibiotics	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.205 %)	Approved	27476412
DrugRepV_1313	Carmustine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.895 %)	Approved	27476412
DrugRepV_1314	Gemfibrozil	Cardiovascular agents	Hyperlipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.965 %)	Approved	27476412
DrugRepV_1315	Flurbiprofen	Musculo-Skeletal System	Rheumatoid arthritis | Osteorarthritis | Anklosing spondylitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.215 %)	Approved, Investigational	27476412
DrugRepV_1316	Dexamethasone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Dermatologicals; Systemic H	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.47 %)	Approved	27476412
DrugRepV_1317	Esmolol	Cardiovascular agents	Cardiovascular disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.035 %)	Approved	27476412
DrugRepV_1318	Carboplatin	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.525 %)	Approved	27476412
DrugRepV_1319	Gefitinib	Antineoplastic and Immunomodulating Agents	Non-small cell lung cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.195 %)	Approved, Investigational	27476412
DrugRepV_1320	Hydroxychloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.595 %)	Approved	27476412
DrugRepV_1321	Sulfamethoxazole	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.87 %)	Approved	27476412
DrugRepV_1322	Misoprostol	Alimentary Tract and Metabolism	Gastric ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.33 %)	Approved	27476412
DrugRepV_1323	Eprosartan Mesylate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.265 %)	Approved	27476412
DrugRepV_1324	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.58 %)	Approved, Investigational	27476412
DrugRepV_1325	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.51 %)	Approved	27476412
DrugRepV_1326	Sulfadiazine	Antiinfectives For Systemic Use	Rheumatic fever | Meningococcal meningitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.975 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1327	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.81 %)	Approved	27476412
DrugRepV_1328	Liothyronine Sodium	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hypothyroidism | Thyroid cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.935 %)	Approved, Vet approved	27476412
DrugRepV_1329	Mesalamine	Alimentary Tract and Metabolism	Ulcerative colitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.935 %)	Approved	27476412
DrugRepV_1330	Methyldopa Sesquihydrate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.48 %)	Approved	27476412
DrugRepV_1331	Propafenone Hydrochloride	Cardiovascular agents	Paroxysmal atrial fibrillation/flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.065 %)	Approved	27476412
DrugRepV_1332	Mometasone Furoate	Dermatologicals and Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.31 %)	Approved, Vet approved	27476412
DrugRepV_1333	Minoxidil	Cardiovascular agents; Dermatologicals	Hypertension | Alopecia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.195 %)	Approved, Investigational	27476412
DrugRepV_1334	Pamidronic Acid	Musculo-Skeletal System	Hypercalcemia associated with malignancy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48 %)	Approved	27476412
DrugRepV_1335	Promethazine Hydrochloride	Respiratory System	Allergic disorders | Nausea/vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.26 %)	Approved, Investigational	27476412
DrugRepV_1336	Ibandronate Sodium Monohydrate	Musculo-Skeletal System	Osteoporosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.185 %)	Approved	27476412
DrugRepV_1337	Phytonadione	NA	Haemorrhagic conditions in infants | Antidote for coumarin anticoagulants in hypoprothrombinaemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.655 %)	Approved, Investigational	27476412
DrugRepV_1338	Lenalidomide	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.155 %)	Approved	27476412
DrugRepV_1339	Bleomycin Sulfate	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.675 %)	Approved	27476412
DrugRepV_1340	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.185 %)	Approved, Investigational	27476412
DrugRepV_1341	Miconazole	Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective	Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.55 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1342	Hydroflumethiazide	Cardiovascular agents	Edema | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.285 %)	Approved, Investigational	27476412
DrugRepV_1343	Articaine Hydrochloride	Nervous System	Anaesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.825 %)	Approved	27476412
DrugRepV_1344	Amantadine Hydrochloride	Nervous System	Influenza and Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.43 %)	Approved	27476412
DrugRepV_1345	Anagrelide	Antineoplastic and Immunomodulating Agents	Thrombocytosis and chronic myeloid leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.7 %)	Approved	27476412
DrugRepV_1346	Dolasetron	Alimentary Tract and Metabolism	Nausea and vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.42 %)	Approved	27476412
DrugRepV_1347	Hydrocortisone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Dermatoses | Immune and allergic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.325 %)	Approved, Vet approved	27476412
DrugRepV_1348	Hydrocortisone Acetate	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Dermatoses | Immune and allergic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.6 %)	Approved	27476412
DrugRepV_1349	Tolazamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.11 %)	Approved	27476412
DrugRepV_1350	Tobramycin	Antiinfectives For Systemic Use; Sensory Organ	Pseudomonas Aeruginosa (Bacteria) lung infections | Sinus infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.055 %)	Approved, Investigational	27476412
DrugRepV_1351	Sulfasalazine	Alimentary Tract and Metabolism	Inflammatory bowel diseases | Crohn disease | Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.285 %)	Approved	27476412
DrugRepV_1352	Gatifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, sinusitis, Community-acquired pneumonia, and Skin infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.98 %)	Approved, Investigational	27476412
DrugRepV_1353	Tetrahydrozoline Hydrochloride	NA	Discomfort and redness of the eye due to minor eye irritations	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.315 %)	Approved	27476412
DrugRepV_1354	Desoximetasone	Dermatologicals	Dermatoses, skin allergies and psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.515 %)	Approved	27476412
DrugRepV_1355	Isoproterenol Hydrochloride	Cardiovascular agents; Respiratory System	Heart block	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.86 %)	Approved, Investigational	27476412
DrugRepV_1356	Fomepizole	Various	Ethylene glycol poisoning	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.72 %)	Approved, Vet approved	27476412
DrugRepV_1357	Desvenlafaxine Succinate Hydrate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.305 %)	Approved	27476412
DrugRepV_1358	Levocarnitine	Alimentary Tract and Metabolism	Carnitine deficiency | Hyperlipoproteinemias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.09 %)	Approved, Investigational	27476412
DrugRepV_1359	Lactulose	Alimentary Tract and Metabolism	Constipation | Hepatic encephalopathy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.74 %)	Approved	27476412
DrugRepV_1360	Bumetanide	Cardiovascular agents	Edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.355 %)	Approved	27476412
DrugRepV_1361	Fenoldopam Mesylate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.23 %)	Approved	27476412
DrugRepV_1362	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.965 %)	Approved	27476412
DrugRepV_1363	Montelukast Sodium	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.9 %)	Approved	27476412
DrugRepV_1364	Telbivudine	Antiinfectives For Systemic Use	Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.765 %)	Approved	27476412
DrugRepV_1365	Budesonide	Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System	Crohn disease, asthma and rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.745 %)	Approved	27476412
DrugRepV_1366	Granisetron Hydrochloride	Alimentary Tract and Metabolism	Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.96 %)	Approved, Investigational	27476412
DrugRepV_1367	Dexmedetomidine Hydrochloride	Nervous System	Sedative therapy, pain relief , anxiety reduction and analgesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.065 %)	Approved	27476412
DrugRepV_1368	Quinine Hydrochloride Hydrate	Antiparasitic products, Insectisides and Repellents	Malaria | Leg cramps	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.065 %)	Approved	27476412
DrugRepV_1369	Fluconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.98 %)	Approved, Investigational	27476412
DrugRepV_1370	Sumatriptan Succinate	Nervous System	Migraine disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.465 %)	Approved, Investigational	27476412
DrugRepV_1371	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.07 %)	Approved	27476412
DrugRepV_1372	Tranylcypromine Hemisulfate	Nervous System	Depressive episode without melancholia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.615 %)	Approved, Investigational	27476412
DrugRepV_1373	Olsalazine Sodium	Alimentary Tract and Metabolism	Inflammatory Bowel Disease | Ulcerative Colitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.435 %)	Approved	27476412
DrugRepV_1374	Gabapentin	Nervous System	Epilepsy (seizure)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.8 %)	Approved	27476412
DrugRepV_1375	Cysteamine Hydrochloride	Sensory Organ	Radiation sickness, cystinosis and cystinurea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.955 %)	Approved	27476412
DrugRepV_1376	Betaine	Alimentary Tract and Metabolism	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.565 %)	Approved, Nutraceutical	27476412
DrugRepV_1377	Halobetasol Propionate	Dermatologicals	Dermatoses	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.565 %)	Approved	27476412
DrugRepV_1378	Tizanidine Hydrochloride	Musculo-Skeletal System	Muscle spasms | Multiple sclerosis | Stroke | Acquired brain injury or a Spinal cord injury	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.39 %)	Approved, Investigational	27476412
DrugRepV_1379	Risedronic Acid	Musculo-Skeletal System	Paget's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.505 %)	Approved	27476412
DrugRepV_1380	Ampicillin Trihydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.895 %)	Approved	27476412
DrugRepV_1381	Amifostine	Various	Nephrotoxicity and Xerostomia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.31 %)	Approved	27476412
DrugRepV_1382	Foscarnet Sodium	Antiinfectives For Systemic Use	Cytomegalovirus retinitis | Herpesviruses | Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.945 %)	Approved	27476412
DrugRepV_1383	Altretamine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.56 %)	Approved	27476412
DrugRepV_1384	Hydroxyzine Dihydrochloride	Nervous System	Anxiety | Tension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.005 %)	Approved	27476412
DrugRepV_1385	Enalapril	Cardiovascular agents	Hypertension and Diabetic nephropathies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.605 %)	Approved	27476412
DrugRepV_1386	Dantrolene Sodium	Musculo-Skeletal System	Malignant hyperthermia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.04 %)	Approved	27476412
DrugRepV_1387	Indapamide	Cardiovascular agents	Hypertension | Edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.8 %)	Approved	27476412
DrugRepV_1388	Tiotropium Bromide	Respiratory System	Chronic obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.135 %)	Approved	27476412
DrugRepV_1389	Diazoxide	Cardiovascular agents	Hypertension, hyperinsulinemic and hypoglycemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.04 %)	Approved	27476412
DrugRepV_1390	Mexiletine Hydrochloride	Cardiovascular agents	Ventricular tachycardia | Symptomatic premature ventricular beats	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.255 %)	Approved, Investigational	27476412
DrugRepV_1391	Nitrofurantoin	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.26 %)	Approved	27476412
DrugRepV_1392	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.76 %)	Approved	27476412
DrugRepV_1393	Sulconazole Nitrate	Dermatologicals	Fungal infections (Tinea cruris and Tinea corporis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.21 %)	Approved	27476412
DrugRepV_1394	Tinidazole	NA	Trichomonasis | Amebiasis | Giardiasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.3 %)	Approved	27476412
DrugRepV_1395	Dicyclomine Hydrochloride	Alimentary Tract and Metabolism	Bowel/irritable bowel syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.09 %)	Approved	27476412
DrugRepV_1396	Diclofenac Sodium salt	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.66 %)	Approved	27476412
DrugRepV_1397	Atenolol	Cardiovascular agents	Hypertension and angina pectoris	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.835 %)	Approved	27476412
DrugRepV_1398	Trimipramine Maleate	Nervous System	Anxiety, Agitation or Sleep disturbance	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.4 %)	Approved	27476412
DrugRepV_1399	Ondansetron	Alimentary Tract and Metabolism	Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.655 %)	Approved	27476412
DrugRepV_1400	Betamethasone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Edocrine disorders, rheumatic disorders, collagen diseases	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.4 %)	Approved	27476412
DrugRepV_1401	Cortisone Acetate	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Allergies, skin problems, asthma and arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.925 %)	Approved	27476412
DrugRepV_1402	Loteprednol Etabonate	Sensory Organ	Allergic conjunctivitis | Uveitis | Acne rosacea | Superficial punctate keratitis | Herpes zoster keratitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.55 %)	Approved	27476412
DrugRepV_1403	Tamsulosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.555 %)	Approved, Investigational	27476412
DrugRepV_1404	Ketotifen Fumarate	Respiratory System	Atopic asthma | Conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.43 %)	Approved	27476412
DrugRepV_1405	Glyburide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.39 %)	Approved	27476412
DrugRepV_1406	Permethrin	Antiparasitic products, Insectisides and Repellents	Scabies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.93 %)	Approved, Investigational	27476412
DrugRepV_1407	Amrinone	Cardiovascular agents	Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.125 %)	Approved	27476412
DrugRepV_1408	Clobetasol Propionate	Dermatologicals	Psoriasis and dermatosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.13 %)	Approved	27476412
DrugRepV_1409	Artemether	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.96 %)	Approved	27476412
DrugRepV_1410	Hydralazine Hydrochloride	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.67 %)	Approved	27476412
DrugRepV_1411	Topotecan Hydrochloride	Antineoplastic and Immunomodulating Agents	Ovarian cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.14 %)	Approved, Investigational	27476412
DrugRepV_1412	Nifedipine	Cardiovascular agents	Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.03 %)	Approved	27476412
DrugRepV_1413	Dexrazoxane	Various	Cardiomyopathy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.42 %)	Approved	27476412
DrugRepV_1414	Fosinopril Sodium	Cardiovascular agents	Hypertension | Congestive heart failure | Renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.225 %)	Approved	27476412
DrugRepV_1415	Capecitabine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.405 %)	Approved	27476412
DrugRepV_1416	Rifapentine	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.79 %)	Approved, Investigational	27476412
DrugRepV_1417	Difluprednate	NA	Anterior uveitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.575 %)	Approved	27476412
DrugRepV_1418	Letrozole	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.705 %)	Approved, Investigational	27476412
DrugRepV_1419	Clavulanate Potassium	Antibacterial	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.97 %)	Approved	27476412
DrugRepV_1420	Nadolol	Cardiovascular agents	Arrhythmias | Angina pectoris | Hypertension | Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.93 %)	Approved	27476412
DrugRepV_1421	Tramadol Hydrochloride	Nervous System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.36 %)	Approved, Investigational	27476412
DrugRepV_1422	Allopurinol	Musculo-Skeletal System	Hyperuricemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.775 %)	Approved	27476412
DrugRepV_1423	Leucovorin Calcium Pentahydrate	Various	Osteosarcoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.875 %)	Approved	27476412
DrugRepV_1424	Levetiracetam	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.66 %)	Approved, Investigational	27476412
DrugRepV_1425	Fluticasone propionate	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.92 %)	Approved	27476412
DrugRepV_1426	Terbutaline Hemisulfate	Respiratory System	Bronchospasm	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.52 %)	Approved	27476412
DrugRepV_1427	Furosemide	Cardiovascular agents	Edema and Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.555 %)	Approved, Vet approved	27476412
DrugRepV_1428	Rufinamide	Nervous System	Seizure disorder :- Lennox-Gastuat syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.69 %)	Approved	27476412
DrugRepV_1429	Nizatidine	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) | Peptic ulcer disease | Active benign gastric ulcer | Active duodenal ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.075 %)	Approved	27476412
DrugRepV_1430	Darifenacin Hydrobromide	Genito Urinary System and Sex Hormones	Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.55 %)	Approved	27476412
DrugRepV_1431	Biperiden Hydrochloride	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.17 %)	Approved	27476412
DrugRepV_1432	Bendroflumethiazide	Cardiovascular agents	Familial hyperkalemia, hypertension, edema, and urinary tract disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.345 %)	Approved	27476412
DrugRepV_1433	Idoxuridine	Antiinfectives For Systemic Use	Keratoconjunctivitis and Keratitis caused by herpes simplex virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.78 %)	Approved, Investigational	27476412
DrugRepV_1434	Leflunomide	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.89 %)	Approved, Investigational	27476412
DrugRepV_1435	Imipramine Hydrochloride	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.665 %)	Approved	27476412
DrugRepV_1436	Telmisartan	Cardiovascular agents	Hypertension | Type 2 diabetes mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.505 %)	Approved, Investigational	27476412
DrugRepV_1437	Bendamustine Hydrochloride	Antineoplastic and Immunomodulating Agents	Chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.125 %)	Approved	27476412
DrugRepV_1438	Rocuronium Bromide	Musculo-Skeletal System	Muscle fasciculation caused by succinylcholine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.025 %)	Approved	27476412
DrugRepV_1439	Triptorelin Acetate	Antineoplastic and Immunomodulating Agents	Advanced prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.535 %)	Approved	27476412
DrugRepV_1440	Levothyroxine Sodium	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hypothyroidism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.275 %)	Approved	27476412
DrugRepV_1441	Diltiazem Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.9 %)	Approved	27476412
DrugRepV_1442	Lisinopril dihydrate	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.825 %)	Approved, Investigational	27476412
DrugRepV_1443	Amoxapine	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.49 %)	Approved	27476412
DrugRepV_1444	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.21 %)	Approved	27476412
DrugRepV_1445	Ethacrynic Acid	Cardiovascular agents	Edema, hypertension and congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.32 %)	Approved	27476412
DrugRepV_1446	Orphenadrine Citrate	Musculo-Skeletal System	Parkinson's disease | Muscle spasm	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.71 %)	Approved	27476412
DrugRepV_1447	Escitalopram	Nervous System	Major depressive disorder and generalized anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.27 %)	Approved	27476412
DrugRepV_1448	Chlorambucil	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.315 %)	Approved	27476412
DrugRepV_1449	Bethanechol Chloride	Nervous System	Neurogenic bladder dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.03 %)	Approved	27476412
DrugRepV_1450	Valacyclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.35 %)	Approved	27476412
DrugRepV_1451	Nelarabine	Antineoplastic and Immunomodulating Agents	T-cell acute lymphoblastic leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.83 %)	Approved, Investigational	27476412
DrugRepV_1452	Doxepin Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.49 %)	Approved	27476412
DrugRepV_1453	Verapamil Hydrochloride	Cardiovascular agents	Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders).	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.75 %)	Approved	27476412
DrugRepV_1454	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.17 %)	Approved	27476412
DrugRepV_1455	Fluocinolone Acetonide	Cardiovascular agents; Dermatologicals; Sensory Organ; Sensory Organ	Chronic non-infectious uveitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.16 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1456	Mifepristone	Genito Urinary System and Sex Hormones	Hypercortisolism | Nonpituitary cushing syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.56 %)	Approved	27476412
DrugRepV_1457	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.8 %)	Approved	27476412
DrugRepV_1458	Mechlorethamine Hydrochloride	Antineoplastic and Immunomodulating Agents	Hodgkin's disease | Lymphosarcoma | Chronic myelocytic or chronic lymphocytic leukemia | Polycythemia vera | Mycosis fungoides | Bronchogenic carcinoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.89 %)	Approved, Investigational	27476412
DrugRepV_1459	Asenapine Maleate	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.345 %)	Approved	27476412
DrugRepV_1460	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.985 %)	Approved	27476412
DrugRepV_1461	Benztropine Mesylate	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.365 %)	Approved	27476412
DrugRepV_1462	Nabumetone	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.66 %)	Approved	27476412
DrugRepV_1463	Dextromethorphan	Respiratory System	Cough	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.605 %)	Approved	27476412
DrugRepV_1464	Diphenhydramine Hydrochloride	Dermatologicals and Respiratory System	Vertigo/Meniere disease, nausea and vomiting, motion sickness and insect bite	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.965 %)	Approved	27476412
DrugRepV_1465	Protriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.31 %)	Approved	27476412
DrugRepV_1466	Hydrochlorothiazide	Cardiovascular agents	High blood pressure | Edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.61 %)	Approved, Vet approved	27476412
DrugRepV_1467	Bosentan	Cardiovascular agents	Pulmonary artery hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.61 %)	Approved	27476412
DrugRepV_1468	Isradipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.02 %)	Approved, Investigational	27476412
DrugRepV_1469	Thiotepa	Antineoplastic and Immunomodulating Agents	Breast cancer | Ovarian cancer | Bladder cancer | Bone marrow transplantation	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.125 %)	Approved, Investigational	27476412
DrugRepV_1470	Enalaprilat Maleate	Cardiovascular agents	Hypertension and symptomatic congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.67 %)	Approved	27476412
DrugRepV_1471	Cytarabine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.14 %)	Approved	27476412
DrugRepV_1472	Terbinafine Hydrochloride	Dermatologicals	Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.665 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1473	Tolterodine Tartrate	Genito Urinary System and Sex Hormones	Overactive bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.97 %)	Approved, Investigational	27476412
DrugRepV_1474	Isocarboxazid	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.14 %)	Approved	27476412
DrugRepV_1475	Imatinib Mesylate	Antineoplastic and Immunomodulating Agents	Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.475 %)	Approved	27476412
DrugRepV_1476	Benazepril Hydrochloride	Cardiovascular agents	Hypertension, congestive heart failure and chronic renal failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.975 %)	Approved	27476412
DrugRepV_1477	Alendronate Sodium trihydrate	Musculo-Skeletal System	Paget disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.805 %)	Approved	27476412
DrugRepV_1478	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.68 %)	Approved	27476412
DrugRepV_1479	Etoposide	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.21 %)	Approved	27476412
DrugRepV_1480	Clemastine Fumarate	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.7 %)	Approved	27476412
DrugRepV_1481	Cyclobenzaprine Hydrochloride	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.705 %)	Approved	27476412
DrugRepV_1482	Rifabutin	Antiinfectives For Systemic Use	Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (35.56 %)	Approved, Investigational	27476412
DrugRepV_1483	Adenosine	Cardiovascular agents	Arrhythmia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.51 %)	Approved	27476412
DrugRepV_1484	Fluvoxamine Maleate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.14 %)	Approved, Investigational	27476412
DrugRepV_1485	Tadalafil	Genito Urinary System and Sex Hormones	Erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.655 %)	Approved	27476412
DrugRepV_1486	Oseltamivir Phosphate	Antiinfectives For Systemic Use	Influenza A/B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.305 %)	Approved	27476412
DrugRepV_1487	Mitotane	Antineoplastic and Immunomodulating Agents	Adrenocortical tumours | Cushing's syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.98 %)	Approved	27476412
DrugRepV_1488	Venlafaxine Hydrochloride	Nervous System	Depression | General anxiety disorder | Social phobia | Panic disorder | vasomotor symptoms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.34 %)	Approved	27476412
DrugRepV_1489	Atomoxetine Hydrochloride	Nervous System	Attention-deficit hyperactivity disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.265 %)	Approved	27476412
DrugRepV_1490	Desonide	Dermatologicals	Inflammatory disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.765 %)	Approved	27476412
DrugRepV_1491	Propranolol Hydrochloride	Cardiovascular agents	Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.09 %)	Approved, Investigational	27476412
DrugRepV_1492	Desipramine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.2 %)	Approved	27476412
DrugRepV_1493	Sirolimus	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressant)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.38 %)	Approved, Investigational	27476412
DrugRepV_1494	Melphalan	Antineoplastic and Immunomodulating Agents	Multiple myeloma | Palliation of non-resectable epithelial carcinoma of the ovary	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.86 %)	Approved	27476412
DrugRepV_1495	Homatropine Methylbromide	Sensory Organ	Peptic ulcer | Gastric ulcer | Duodenal ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.29 %)	Approved	27476412
DrugRepV_1496	Cabergoline	Genito Urinary System and Sex Hormones; Nervous System	Hyperprolactinemic disorders and Parkinsonian Syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (33.37 %)	Approved	27476412
DrugRepV_1497	Aminocaproic Acid	Blood and Blood Forming Organs	Antifibrinolytic agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.285 %)	Approved	27476412
DrugRepV_1498	Desloratadine	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.02 %)	Approved	27476412
DrugRepV_1499	Lapatinib Ditosylate	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.875 %)	Approved, Investigational	27476412
DrugRepV_1500	Doxazosin Mesylate	Cardiovascular agents	Hypertension and Hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.835 %)	Approved	27476412
DrugRepV_1501	Rimantadine Hydrochloride	Antiinfectives For Systemic Use	Influenza A virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.755 %)	Approved, Investigational	27476412
DrugRepV_1502	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (36.42 %)	Approved	27476412
DrugRepV_1503	Everolimus	Antineoplastic and Immunomodulating Agents	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (33.77 %)	Approved	27476412
DrugRepV_1504	Oxaliplatin	Antineoplastic and Immunomodulating Agents	Colon Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.1 %)	Approved, Investigational	27476412
DrugRepV_1505	Dimenhydrinate	Respiratory System; Dermatologicals	Antimuscarinic, and motion sickness	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (36.59 %)	Approved	27476412
DrugRepV_1506	Nimodipine	Cardiovascular agents	Subarachnoid hemorrhage (SAH)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.835 %)	Approved, Investigational	27476412
DrugRepV_1507	Loratadine	Respiratory System	Rhinitis | Urticaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.655 %)	Approved, Investigational	27476412
DrugRepV_1508	Butoconazole Nitrate	Genito Urinary System and Sex Hormones	Vulvovaginal candidiasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.275 %)	Approved	27476412
DrugRepV_1509	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.79 %)	Approved, Vet approved	27476412
DrugRepV_1510	Amitriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.4 %)	Approved	27476412
DrugRepV_1511	Acyclovir Zovirax	NA	Viral infections (Herpes simplex, Zoster and varicella zoster)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.46 %)	Approved	27476412
DrugRepV_1512	Fludarabine phosphate	Antineoplastic and Immunomodulating Agents	Hematological malignancies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.445 %)	Approved	27476412
DrugRepV_1513	Loxapine succinate	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.465 %)	Approved	27476412
DrugRepV_1514	Reserpine	Cardiovascular agents	Hypertension | Psychotic disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.15 %)	Approved, Investigational	27476412
DrugRepV_1515	Adapalene	Dermatologicals	Acne vulgaris	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.305 %)	Approved	27476412
DrugRepV_1516	Saquinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (32.635 %)	Approved, Investigational	27476412
DrugRepV_1517	Telithromycin	Antiinfectives For Systemic Use	Pneumococcal infection | Acute sinusitis | Acute bacterial tonsillitis | Acute bronchitis and bronchiolitis | Lower respiratory tract infection and lobar (pneumococcal) pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.37 %)	Approved	27476412
DrugRepV_1518	Amlodipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (26.615 %)	Approved	27476412
DrugRepV_1519	Cladribine	Antineoplastic and Immunomodulating Agents	Lymphoproliferative diseases	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.775 %)	Approved	27476412
DrugRepV_1520	Cyproheptadine Hydrochloride Sesquihydrate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.41 %)	Approved	27476412
DrugRepV_1521	Irinotecan Hydrochloride	Antineoplastic and Immunomodulating Agents	Colorectal cancer | Small cell lung cancer | Cervical cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (30.47 %)	Approved, Investigational	27476412
DrugRepV_1522	Streptomycin Sulfate	Antiinfectives For Systemic Use	Tuberculosis | Tularemia | Plague | Brucellosis | Endocarditis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (28.56 %)	Approved, Vet approved	27476412
DrugRepV_1523	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (29.485 %)	Approved, Investigational	27476412
DrugRepV_1524	Teniposide	Antineoplastic and Immunomodulating Agents	Acute lymphoblastic leukaemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (26.615 %)	Approved	27476412
DrugRepV_1525	Tamoxifen Citrate	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (27.085 %)	Approved	27476412
DrugRepV_1526	Celecoxib	Musculo-Skeletal System	Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (29.635 %)	Approved	27476412
DrugRepV_1527	Indomethacin	Cardiovascular agents; Musculo-Skeletal System; Musculo-Skeletal System	Rheumatoid arthritis | Ankylosing spondylitis | Osteoarthritis | Acute painful shoulder (bursitis and/or tendinitis) | Acute gouty arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.73 %)	Approved, Investigational	27476412
DrugRepV_1528	Temsirolimus	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (20.73 %)	Approved	27476412
DrugRepV_1529	Desogestrel	Genito Urinary System and Sex Hormones	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (21.195 %)	Approved	27476412
DrugRepV_1530	Clindamycin Palmitate Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (22.29 %)	Approved	27476412
DrugRepV_1531	Felodipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (25.83 %)	Approved, Investigational	27476412
DrugRepV_1532	Aprepitant	Alimentary Tract and Metabolism	Nausea and vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (19.16 %)	Approved	27476412
DrugRepV_1533	Mitoxantrone Hydrochloride	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (0.635 %)	Approved, Investigational	27476412
DrugRepV_1554	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1555	Pyrimethamine	Antiparasitic products, Insectisides and Repellents	Toxoplasmosis | Acute malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	No significant effect	Approved, Investigational, Vet approved	27476412
DrugRepV_1556	Azathioprine	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis.	Zika virus	MEX_I_7	NA	Fluorescence-based assay	No significant effect	Approved	27476412
DrugRepV_1557	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_1558	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_1559	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	No significant effect	Approved	27476412
DrugRepV_1560	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	27476412
DrugRepV_1561	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_4498	Ranpirnase	Anticancer	Cancer	Ebola virus	Kikwit	NA	Fluorescence-based assay	Decrease	Investigational	27350309
DrugRepV_5094	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Fluorescence-based assay	Decrease (3 log FFU/ml)	Investigational	16372299
DrugRepV_5095	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Fluorescence-based assay	No significant effect (2 fold FFU/ml)	Investigational	16372299
DrugRepV_5098	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (50 %)	Approved	29024765
DrugRepV_5099	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	29024765
DrugRepV_5100	2-Deoxy-2-fluorocytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (50 %)	NA	29024765
DrugRepV_5101	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (50 %)	Approved	29024765
DrugRepV_5102	2-Chloroadenosine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-26 %)	NA	29024765
DrugRepV_5103	2-Deoxy-2-fluorocytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (98 %)	NA	29024765
DrugRepV_5104	2-C-Methylcytidine	NA	HCV	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (4 %)	Experimental	29024765
DrugRepV_5105	2-C-Methyluridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-9 %)	NA	29024765
DrugRepV_5106	2-O-Methylcytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	NA	29024765
DrugRepV_5107	2-O-Methyluridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	NA	29024765
DrugRepV_5108	3-Deazauridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (19 %)	NA	29024765
DrugRepV_5109	5-Azacytidine	Antineoplastic and Immunomodulating Agents	Anemia	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (0 %)	Approved	29024765
DrugRepV_5110	5-Azidouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (28 %)	NA	29024765
DrugRepV_5111	5-Bromouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (1 %)	NA	29024765
DrugRepV_5112	5-Chlorouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (0 %)	NA	29024765
DrugRepV_5113	5-Fluorouridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	Experimental	29024765
DrugRepV_5114	5-Methylcytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (6 %)	NA	29024765
DrugRepV_5115	6-Aza-2-thiouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (17 %)	NA	29024765
DrugRepV_5116	6-Azauridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (36 %)	NA	29024765
DrugRepV_5117	7-DMA	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (26 %)	NA	29024765
DrugRepV_5118	8-Azaadenosine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (92 %)	NA	29024765
DrugRepV_5119	8-Azidoadenosine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (87 %)	NA	29024765
DrugRepV_5120	ABT-333	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (39 %)	Approved	29024765
DrugRepV_5121	Balapiravir	Antiviral	Viral infection (Dengue and Hepatitis C, Chronic)	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	Investigational	29024765
DrugRepV_5122	BCX4430	NA	Ebola virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (18 %)	Investigational	29024765
DrugRepV_5123	Cordycepine	Anticancer	Leukemia	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (12 %)	Investigational	29024765
DrugRepV_5124	Gleevec	Antineoplastic and Immunomodulating Agents	Leukemia	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (26 %)	Approved	29024765
DrugRepV_5125	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (24 %)	Approved	29024765
DrugRepV_5126	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (99 %)	Approved	29024765
DrugRepV_5127	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (99 %)	Approved, Investigational	29024765
DrugRepV_5128	NITD008	Antiviral	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-23 %)	NA	29024765
DrugRepV_5129	PSI-6130	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-6 %)	NA	29024765
DrugRepV_5130	PSI-6206	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-1 %)	NA	29024765
DrugRepV_5131	PSI-7976	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (9 %)	NA	29024765
DrugRepV_5132	PSI-7977	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (4 %)	Approved	29024765
DrugRepV_5133	R-1479	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (15 %)	NA	29024765
DrugRepV_5134	R-7128	Antiviral	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-1 %)	Investigational	29024765
DrugRepV_5135	RO-9187	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (12 %)	NA	29024765
DrugRepV_5136	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (2 %)	Approved	29024765
DrugRepV_5137	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (26 %)	Approved, Investigational	29024765
DrugRepV_5138	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (88 %)	Investigational	29024765
DrugRepV_5139	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (0 %)	Approved, Investigational	29024765
DrugRepV_5140	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (27 %)	Approved	29024765
DrugRepV_5160	Benzavir-2	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	29386590
DrugRepV_5161	Benzavir-1	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	29386590
DrugRepV_5162	2-[[4-chloro-2-[(2-fluorobenzoyl)amino]benzoyl]amino]benzoic acid	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	29386590
DrugRepV_5163	2-[[2-(2,2-dimethylpropanoylamino)benzoyl]amino]benzoic acid	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	No significant effect (50 %)	NA	29386590
DrugRepV_5164	2-[[2-(cyclohexanecarbonylamino)benzoyl]amino]benzoic acid	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	No significant effect (50 %)	NA	29386590
DrugRepV_5171	3-(2,3-Diphenyl-1H-indol-1-yl)-N-(3-hydroxybenzylidene) propanohydrazide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5172	1-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-(2-imino-3-(4-methylbenzyl)-2,3- dihydro-1H-benzimidazol-1-yl)ethanone hydrobromide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5173	4-Hydroxy-3-methoxybenzaldehyde (4-(3,4-dimethoxyphenyl)-6-phenyl-2- pyrimidinyl)hydrazone	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5174	1-(3,4-Dichlorophenyl)-3-(4-(3,4-dimethoxyphenyl)-1-methylpyrrolidin-3- yl)urea	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5175	2-Chloro-N-(2-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-ylcarbamoyl)phenyl) benzamide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5176	2-(4-Bromo-5-chlorothiophene-2-sulfonamido)-N-(4-fluorophenyl) benzamide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5177	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Rift Valley fever virus	MP12	NA	Fluorescence-based assay	Decrease (1 log Resazurin fluorescence)	Investigational	25267680
DrugRepV_5713	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5714	Carrageenan	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5715	Tannic Acid	NA	Cold sores | Diaper rash | Fever blisters | Poison ivy	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5716	Tannic Acid	NA	Cold sores | Diaper rash | Fever blisters | Poison ivy	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5717	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Investigational	20973722
DrugRepV_5718	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Investigational	20973722
DrugRepV_5719	Antimycin A	Antifungal	Fungal infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5720	Antimycin A	Antifungal	Fungal infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5721	BIBU 1361	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5722	BIBU 1361	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5723	Acetylspiramycin	Antiinfectives For Systemic Use	Microbial infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5724	3-[(4-chloro-phenyl)-phenyl-methoxy]-tropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5725	3-[(4-chloro-phenyl)-phenyl-methoxy]-tropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5726	Bebeerine	Antiparasitic	Malaria	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5727	H-89	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5728	H-89	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5729	MPP	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5730	MPP	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5731	Benzethonium	Respiratory System	Topical microbial infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5732	Benzethonium	Respiratory System	Topical microbial infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5733	Selamectin	Antiparasitic	Vet-Antihelminthic	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Vet approved	20973722
DrugRepV_5734	W-9	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5735	W-9	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5736	AZ 10417808	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5737	AZ 10417808	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5738	Niguldipine	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Experimental	20973722
DrugRepV_5739	Niguldipine	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Experimental	20973722
DrugRepV_5740	3a-bis-(4-fluorophenyl) Methoxytropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5741	LE 135	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5742	LE 135	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722